TREATMENT SUPPORT INFORMATION AND / OR TRACKING DEVICE AND ASSOCIATED METHODS AND SYSTEMS

Abstract

To provide methods, systems and devices that assist a user in making appropriate therapeutic decisions while minimizing burdens on the user.SOLUTION: A monitoring feature, such as a pen cap, for an insulin delivery device may include at least one circuit adapted to detect uncapping and / or capping of an insulin pen with the pen cap, and a processor for using information on the uncapping and / or capping with the pen cap. A monitoring feature for an insulin delivery device includes at least one circuit adapted to detect use of the insulin delivery device.SELECTED DRAWING: Figure 1A

Description

[Technical Field]

[0001] Priority claims This application claims the benefit of the filing dates of U.S. Provisional Patent Application Nos. 62 / 597,868, entitled "Therapy Assist Information and / or Tracking Device and Related Methods and Systems," filed December 12, 2017; 62 / 597,809, entitled "Medicine Injection and Disease Management Systems, Devices, and Methods," filed December 12, 2017; 62 / 628,808, entitled "Diabetes Therapy Management Systems, Methods and Devices," filed February 9, 2018; and 62 / 682,872, entitled "Diabetes Therapy Management Systems, Methods, and Devices," filed June 9, 2018, the disclosures of each of which are incorporated herein by reference in their entireties.

[0002] The present disclosure relates to therapy management systems, methods, and devices adapted to collect and / or transmit therapy-related data (e.g., timing of therapy) and / or other therapy-related data and provide therapy recommendations to a user. In certain embodiments, diabetes therapy management systems, devices, and methods are disclosed that may be used in conjunction with an insulin infusion device and include components adapted to provide insulin therapy recommendations to a user based on stored therapy parameters, blood glucose data, meal size estimates, and / or other parameters. [Background technology]

[0003] Diabetes mellitus is a chronic metabolic disorder that occurs when a person's pancreas fails to produce sufficient amounts of the hormone insulin, resulting in the person's metabolism being unable to properly absorb sugars and starches. This failure results in hyperglycemia, i.e., the presence of excessive amounts of glucose in the blood plasma. Persistent hyperglycemia is associated with a variety of serious symptoms and life-threatening long-term complications, including dehydration, ketoacidosis, diabetic coma, cardiovascular disease, chronic renal failure, retinal damage, and nerve damage with the risk of limb amputation. Because a cure is currently not possible, permanent treatment is required to provide regular glycemic control to consistently maintain blood analyte concentrations within the normal range. Such glycemic control is achieved by periodically administering topical agents to the patient's body, thereby lowering elevated blood analyte concentrations.

[0004] Biologically active topical agents (e.g., insulin or its analogs) are typically administered by daily injection. In some cases, multiple-dose injections (MDIs) of a mixture of rapid-acting and long-acting insulin are administered via a reusable transdermal liquid administration device (commonly referred to as an "insulin pen") or a hypodermic syringe. Injections are typically administered by the person with diabetes (PWD) and therefore require self-monitoring of blood glucose and self-administration of insulin. PWDs who manage their care using MDIs often pre-plan each day's insulin injections based on basal insulin needs and external factors such as meals, exercise, and sleep. A typical administration plan would include the time of injection, the type of insulin (e.g., rapid-acting, long-acting, a combination of rapid-acting and long-acting, etc.), and the amount of insulin for each administration. Additionally, PWDs self-monitor their blood glucose, administering a "bolus" dose of rapid-acting insulin if blood glucose is too high, or consuming carbohydrates (or possibly administering glycogen) if blood glucose is too low.

[0005] The "right" insulin dose depends on physiological factors such as blood glucose concentration, a person's insulin sensitivity, and lifestyle factors such as diet (e.g., recently consumed carbohydrates that have not yet been metabolized to glucose and absorbed into the blood). Furthermore, even with careful planning and self-monitoring, PWDs may miss doses, duplicate doses, or administer the wrong amount and / or type of insulin. Insufficient insulin can result in hyperglycemia, while too much insulin can result in hypoglycemia, which can lead to clumsiness, difficulty speaking, confusion, loss of consciousness, seizures, or death. Thus, PWDs face a significant cognitive burden when identifying the appropriate insulin dose. Summary of the Invention [Problem to be solved by the invention]

[0006] To assist in self-treatment, some diabetes treatment devices (e.g., blood glucose meters, insulin pumps, etc.) are equipped with insulin bolus calculators that prompt the user to input a prediction (e.g., a numerical prediction) of the amount of carbohydrates consumed or to be consumed (or additionally or instead, protein, fat, or other meal data), and the bolus calculator outputs a recommended size of a bonus insulin dose. Although bolus calculators eliminate some of the mental calculations that must be performed by the user in identifying an appropriate insulin bolus dose, bolus calculators still burden the user with the mental task of evaluating the components of their meal, may require the use of secondary devices, and often require manual entry of data. Thus, a need exists for methods, systems, and devices that assist users in making appropriate therapeutic decisions while minimizing user burden (e.g., data entry, mental calculations, actions, etc.).

[0007] The present disclosure may be more fully understood by reference to the following detailed description of the exemplary embodiments, as illustrated in the accompanying drawings. [Brief explanation of the drawings]

[0008] [Figure 1A] 1 illustrates a diabetes management system according to an embodiment of the present disclosure. [Figure 1B] 1 illustrates certain components of an exemplary diabetes management system. [Figure 1C] 1 illustrates a second exemplary diabetes management system. [Figure 2] 1 illustrates a user using one or more portions of a diabetes management system according to an embodiment of the present disclosure. [Figure 3] 1 illustrates a display on a pen cap according to an embodiment of the present disclosure. [Figure 4] 1 illustrates a display on a pen cap according to an embodiment of the present disclosure. [Figure 5] 1 illustrates a display on a pen cap according to an embodiment of the present disclosure. [Figure 6] 1 illustrates a display on a pen cap according to an embodiment of the present disclosure. [Figure 7] 1 illustrates an exemplary communication architecture of a system according to an embodiment of the present disclosure. [Figure 8] 1 illustrates a process for recommending insulin dosages according to an embodiment of the present disclosure. [Figure 9] 1 illustrates a process for injecting insulin according to an embodiment of the present disclosure. [Figure 10] 1 illustrates a process for recommending insulin dosages according to an embodiment of the present disclosure. [Figure 11] 1 illustrates a process for injecting insulin according to an embodiment of the present disclosure. [Figure 12] 1 illustrates a process for checking the status of a treatment system according to an embodiment of the present disclosure. [Figure 13] 1 illustrates a process for checking the status of a treatment system according to an embodiment of the present disclosure. [Figure 14] 1 illustrates a process for updating treatment information according to an embodiment of the present disclosure. [Figure 15]1 illustrates a process for checking the status of a treatment system according to an embodiment of the present disclosure. [Figure 16] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 17] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 18] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 19] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 20] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 21] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 22] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 23] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 24] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 25] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 26] 1 illustrates an exemplary slide scale chart for a diabetes management system, according to an embodiment of the present disclosure. [Figure 27] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 28] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 29] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 30] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 31] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 32] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 33] 1 illustrates an exemplary display and / or user interface of a portion of a system (e.g., of a mobile device) according to an embodiment of the present disclosure. [Figure 34A] 1 illustrates an exemplary communications architecture for an upgradeable system, according to an embodiment of the present disclosure. [Figure 34B] 1 illustrates an exemplary communications architecture for an upgradeable system, according to an embodiment of the present disclosure. [Figure 34C] 1 illustrates an exemplary communications architecture for an upgradeable system, according to an embodiment of the present disclosure. [Figure 34D] 1 illustrates an exemplary communications architecture for an upgradeable system, according to an embodiment of the present disclosure. [Figure 35A] 1 illustrates an exemplary display on a pen cap according to an embodiment of the present disclosure. [Figure 35B] 1 illustrates an exemplary display on a pen cap according to an embodiment of the present disclosure. DETAILED DESCRIPTION OF THE INVENTION

[0009] Manual insulin delivery devices, such as insulin pens and insulin inhalers (generally referred to herein as "manual insulin devices"), provide a convenient and reusable means of delivering insulin. However, improper administration of insulin due to human error, insulin pen malfunction, missed doses, duplicate doses, and incorrect administration is always a concern. While the methods, devices, and systems provided herein describe the delivery of insulin, collection of blood glucose data, and / or treatment of diabetes, the treatments of the methods, devices, and systems provided herein may be adapted to deliver other medications, collect other analyte data, and / or treat other diseases. Additionally, while the methods, devices, and systems provided herein are primarily described by describing features and functionality included in, or methods using, or systems including, a pen cap accessory for an insulin delivery pen, it is contemplated that the features discussed herein may also be directly incorporated into, or methods or systems including, a smart drug delivery pen, smart drug delivery inhaler, or other accessory affixed to or adapted for use with such a device.

[0010] The systems, devices, and methods described herein may be operated or performed by a user, such as a PWD, patient, subject, medical professional, clinician, and caregiver, respectively. Unless otherwise specified, the terms medical professional, clinician, and caregiver are used interchangeably in this disclosure.

[0011] Generally, the therapy management systems (e.g., diabetes management systems such as insulin therapy management systems), methods, and devices described herein may include a user interface configured to receive user-specific dosage parameters from a user or a healthcare professional and provide recommendations and reports to the user using these user-specific dosage parameters. In some embodiments, the user interface for receiving user-specific dosage parameters may be incorporated into a mobile application or another computing device, and the user interface for displaying instantaneous drug delivery recommendations may be incorporated into a manual drug delivery device or an accessory for a smart manual drug delivery device. In some cases, the user interface for inputting user-specific dosage parameters may additionally be used to display reports, recommendations, warnings, alerts, notifications, and recommended user dosage parameter changes.

[0012] The systems, devices, and methods provided herein can include user interfaces adapted to simplify the entry of treatment-related data to reduce the burden of self-treatment. In some embodiments, the systems, devices, and methods provided herein are adapted to assist a person with diabetes (PWD) or their caregiver in identifying an appropriate insulin dose. In some embodiments, the methods, devices, and systems provided herein can reduce or eliminate manual entry of numerical data after initial setup. In some embodiments, the methods, devices, and systems provided herein can be adapted to simplify blood glucose monitoring. In some embodiments, the methods, devices, and systems provided herein can enable users to carefully manage their own treatment. In some embodiments, the methods, devices, and systems provided herein can reduce the cognitive burden associated with making daily treatment decisions.

[0013] The systems, devices, and methods provided herein can simplify the process for obtaining insulin therapy recommendations and / or simplifying the collection of estimated glucose values ​​(EGVs) and / or insulin delivery data from one or more insulin delivery devices. The systems, devices, and methods provided herein may be designed to minimize changes that may be required to a person with diabetes (PWD) who administers insulin therapy using injections to receive therapy recommendations and / or to receive notifications, alerts, or warnings.

[0014] In some embodiments, the systems, methods, and devices provided herein can provide a user with a choice of when, where, and whether to receive notifications, alerts, or warnings, which can be based at least in part on the device of the system being run by the user. In some embodiments, the warnings and / or alerts can be customized over time based on feedback from the user (e.g., the user's likes and dislikes). In some embodiments, the systems, methods, and devices provided herein can include notifications, alerts, and / or warnings that use a combination of EGV data and insulin delivery data to determine whether to trigger an alert and / or warning.

[0015] In some embodiments, the systems, devices, and methods provided herein can automatically capture insulin delivery data, which can be captured using a connected and / or smart insulin injection pen or using a connected and / or smart insulin pen accessory (e.g., a connected pen cap accessory).

[0016] In some embodiments, the systems, devices, and methods provided herein can recommend insulin dosages (e.g., long-acting and / or rapid-acting insulin dosages) using any suitable technique. In some embodiments, the recommended insulin dosage may be based on blood glucose data (e.g., current EGV from a CGM, flash glucose monitor, blood glucose meter, or any other sensor, blood glucose trend data, etc.), insulin administration data (e.g., rapid-acting insulin bolus dose, long-acting insulin dose, dose number, IOB and / or active insulin calculations, etc.), meal data (e.g., meal time, user-estimated carbohydrates, user-estimated meal category, user-estimated impact of the meal on blood glucose, user's meal history, user's meal trends, etc.), and / or one or more insulin delivery parameters (e.g., total daily basal insulin or long-acting insulin dosage, carbohydrate-to-insulin ratio (CR), insulin sensitivity factor (ISF), etc.). The methods, devices, and systems provided herein, in some embodiments, can adjust insulin delivery parameters over time based on glucose data and / or insulin administration data.

[0017] The systems, devices, and methods provided herein may include or use a mobile device (e.g., a mobile application running on a smartphone or tablet) that allows a user to configure the device or system, check the device or system's status, adjust treatment settings, and / or learn about ways to improve treatment options. In some embodiments, the mobile device may include information about maintenance tasks (e.g., reminders to perform certain maintenance tasks). In some embodiments, the methods, systems, and devices provided herein may detect patterns in treatment-related data and use the data to provide the user with hints, suggestions, alerts, and / or warnings based on the patterns, which may be displayed on the mobile device. In some embodiments, the mobile device may provide the user with a graphical display of the user's treatment-related data and / or treatment decisions (e.g., blood glucose data and / or insulin infusion times). In some embodiments, the mobile device may provide the user with a display recommending that the user adjust their treatment (e.g., the amount of insulin relative to meals, the amount of insulin relative to the user's basal needs, the timing of insulin infusions, etc.) and provide the user with ways (e.g., links) to adjust their treatment. In some embodiments, the mobile device may provide the user with an indication that the system has automatically adjusted the user's treatment (e.g., amount of insulin for meals, amount of insulin for the user's basal needs, timing of insulin infusions, etc.), and may optionally provide a way (e.g., a link) to decline the automatic adjustment, confirm the automatic adjustment, or manually adjust the treatment.

[0018] In some embodiments, the diabetes management systems, devices, and methods provided herein may include multiple meal size categories (e.g., three meal sizes (large, medium, small), time-based meals (breakfast, lunch, dinner, snack)) that can be set by a user (e.g., on a mobile device). In some embodiments, the mobile device includes a setup user interface in which the user is prompted to input the user's typical insulin dosages for different size meals (e.g., dosage for a small meal, dosage for a medium meal, dosage for a large meal). In some embodiments, the setup user interface displays to the user example photos of meals that would be included in each meal category. In some embodiments, the device can analyze the approximate size of the user's meals (e.g., by analyzing input from the user, such as input regarding meal characteristics, meal photos, etc.). In some embodiments, the setup user interface may provide an estimate of what the user is expected to input for each meal size based on the amount of long-acting insulin (e.g., Lantus® dose) entered by the user.

[0019] The systems, devices, and methods provided herein may include, use, or communicate with one or more accessories for a medication delivery device, such as an insulin pen (e.g., a pen cap for an insulin pen), which accessories (a) are adapted to be secured to the injection pen and to detect when the pen cap is secured to the injection pen and / or when the pen cap is released from the injection pen, (b) are adapted to receive blood glucose data from a glucose sensor, and / or (c) are adapted to provide treatment-related information and / or recommendations to a user.

[0020] In some cases, the accessory may be a pen cap accessory adapted to detect pen cap attachment information. The pen cap attachment information (e.g., information regarding when the pen cap was secured to and / or released from the injection pen) may include information regarding the current cap attachment period (e.g., time since last cap attachment), information regarding one or more cap removal times (sometimes referred to herein as "cap removal"), and the timing (e.g., time of day or elapsed time) of each cap removal and each cap attachment. In some embodiments, the pen cap attachment information may be displayed to the user on the pen cap accessory. In some embodiments, the pen cap attachment information may be announced by a speaker within the pen cap. For example, in some embodiments, the pen cap may provide a timer that counts up since the pen cap was last secured to the injection pen. In some embodiments, the pen cap accessory may wirelessly communicate the pen cap attachment information to a remote computing device (e.g., a smartphone, tablet, etc.). In some embodiments that do not include a pen cap accessory, the accessory or smart delivery device may detect other events related to medication delivery operations and use that information in the manner described herein for pen cap attachment information. For example, in some cases, an injection pen accessory is secured to the injection pen so that mechanical movement of the injection mechanism can be detected to time the administration of medication.

[0021] The pen cap wear information may be used to modify the user experience (e.g., the display or information presented to the user). In some embodiments, the pen cap adjusts the presentation of therapy-related information and / or recommendations provided to the user based on the pen cap wear information. For example, in some embodiments, the pen cap may provide a bolus recommendation to correct an elevated blood glucose level based on data from a glucose sensor, but the presentation of such a correction bolus recommendation may be limited to when the current pen cap wear period is longer than a threshold period (e.g., at least 2 hours, at least 3 hours, at least 4 hours, or at least 5 hours). In some embodiments, the pen cap may provide a notification, alert, or warning to the user based on the pen cap wear information. For example, if the pen cap is removed from the injection pen within a threshold period (e.g., within 30 minutes or within 1 hour) of the last cap wear, the pen cap may provide a visual, audible, or vibration notification indicating that the user may have recently administered insulin using the pen. In some embodiments, the pen cap may wirelessly communicate with a mobile computing device (e.g., a smartphone, a tablet), and one or more notifications, alerts, or warnings based on the pen cap attachment information may be announced or displayed on the mobile computing device.

[0022] The pen cap wear information may be stored, displayed, and / or analyzed in combination with glucose data to determine user behavior, such as whether a person is properly administering insulin for meals and / or to correct elevated blood glucose levels. In some embodiments, the pen cap wear information may be presented to the user and / or a medical professional on a graphical display of the user's blood glucose data. In some embodiments, blood glucose data from the period after each cap wear event may be evaluated to determine whether the user properly administered insulin for that cap wear event, e.g., whether they administered adequately, under-administered, or over-administered.

[0023] In some embodiments, a pen capping event may be ignored if other information indicates that no dose was administered. For example, if no change is detected in the insulin pen's dose selection (e.g., dial), the event may be ignored. In some embodiments, a pen capping and recapping event may be ignored if the total capping time is less than a first threshold (e.g., 4-6 seconds). For example, the threshold may be determined by setting a time that is too short to allow for an injection, but long enough to allow the user to check the end of the pen to determine whether any insulin remains or whether there is a needle attached to the pen. In some cases, the total capping time of a capping event (the time between the capping event and the subsequent recapping event) may be analyzed in combination with blood glucose data to determine whether an injection occurred during that capping event. In some cases, if the total capping time exceeds a second threshold period (e.g., at least 15 minutes, at least 30 minutes, etc.), blood glucose data may be used to identify the approximate time of injection.

[0024] The accessories (e.g., pen caps) provided herein, as well as related methods and systems provided herein, may be adapted to obtain blood glucose data for use in providing therapy-related information and / or therapy recommendations via the accessory (e.g., via the pen cap). In some embodiments, the therapy-related information displayed on the pen cap accessory may include the user's current estimated glucose value (EGV). In some embodiments, the therapy-related information displayed on the pen cap may include a current blood glucose trend or rate-of-change indicator (e.g., trend arrow). In some embodiments, the pen cap may include a recommended dosage, which may be based on glucose data or may be based on stored parameters without considering the current EGV.

[0025] The accessories (e.g., pen caps) provided herein may be adapted to receive blood glucose data from any suitable glucose sensor. In some embodiments, the glucose sensor may be a continuous glucose monitor (CGM), a flash glucose monitor, a blood glucose monitor (BGM), or any other suitable sensor. In the case of CGMs and flash glucose monitors, they may be configured to provide glucose data based on a user's interstitial fluid glucose concentration, which may be correlated to a blood glucose level. A BGM may be configured to provide blood glucose data, typically based on a blood sample. Thus, while the term "blood glucose" may sometimes be used simply as a general term for convenience, the present disclosure is not limited to using solely blood glucose data, values, concentrations, etc., but also interstitial fluid glucose concentrations, as well as any intermediate measurements.

[0026] In some embodiments, the pen cap may automatically receive glucose data from the CGM automatically without user interaction as long as the pen cap is within range. In some embodiments, the pen cap may be adapted to wirelessly receive the current EGV (and optionally, the previous EGV) from the flash glucose monitor when the pen cap is positioned in proximity to (e.g., swiped adjacent to) the flash glucose monitor. In some embodiments, the EGV may be obtained via BGM, which may wirelessly communicate with the pen cap or a mobile computing device (which can then transmit the EGV to the pen cap), or may be entered by the user into a remote computing device.

[0027] The accessories provided herein (e.g., pen caps) may, in some embodiments, be configured to retrieve only glucose data related to a user interacting with the pen cap. For example, if the pen cap is adapted to acquire glucose data from a CGM or flash glucose monitor, the pen cap may be designed to require swiping near the CGM or flash glucose monitor, or may be designed to retrieve only glucose data upon user request (e.g., when a button is pressed). In some embodiments, the CGM may wirelessly communicate with a mobile computing device (e.g., smartphone, tablet), and when a button is pressed on the pen cap, only data from the CGM is transferred to the pen cap.

[0028] In some embodiments, the accessories (e.g., pen caps) or mobile applications provided herein can provide reminders to the user to acquire glucose data. For example, in the case of methods and systems including a flash glucose monitor, a reminder may be sent to the user to acquire glucose data by swiping the pen cap near the flash glucose monitor. In some embodiments, the reminders to acquire glucose data can be timed based on pen cap wear information. For example, the reminders to acquire blood glucose data can be determined based on the time since the most recent cap wear (e.g., the duration of the current cap wear exceeding a threshold). In some embodiments, the threshold can be set to reduce the likelihood that an insulin dose may cause a hypoglycemic event. In some embodiments, the pen cap can wirelessly receive blood glucose data and compare it with pen cap wear information to analyze patterns in the blood glucose data to identify potential future hypoglycemic events or predicted future blood glucose levels. In some embodiments, the blood glucose data and pen cap wear information may be wirelessly transmitted to a remote computing device (e.g., smartphone, tablet) and analyzed at the remote computing device or in the cloud or other network or device to identify potential future hypoglycemic events or predicted future blood glucose levels, and may be used to issue notifications, alerts, or warnings and / or set reminders to obtain blood glucose data.

[0029] The pen caps provided herein can use any suitable technology to obtain pen cap attachment information (e.g., information regarding pen cap removal / application during insulin infusion). In some embodiments, the pen caps provided herein can include a biasing element, e.g., a leaf spring inside the cap, that completes a circuit when the pen cap is secured to the injection pen. In other embodiments, the cap can include a sensor (e.g., an optical sensor, a mechanical sensor, an electronic sensor, a magnetic sensor, etc.) that detects when the cap is applied to and / or removed from the pen.

[0030] The accessories (e.g., pen caps), methods, and systems provided herein can use any suitable method for making treatment recommendations. In some embodiments, a user or medical professional can set a recommended dosage for starting the product, set one or more initial carbohydrate-to-insulin ratios, set one or more initial insulin sensitivity factors, create a table of correction doses to be used for a particular range of glucose values, and / or set one or more meal characteristics. For example, in some embodiments, a user or medical professional may set an initial recommended dose of long-acting insulin, as well as a carbohydrate-to-insulin ratio and insulin sensitivity factor to be used in identifying a dose of rapid-acting insulin. In some embodiments, a user or medical professional may set typical meal sizes in carbohydrates for breakfast, lunch, and / or dinner. In some embodiments, a user or medical professional may set the user's typical meal-based rapid-acting insulin doses for breakfast, lunch, and dinner. In some embodiments, a user or medical professional may set characteristics for different meal sizes (large (L), medium (M), small (S)) for different times of day (e.g., 10 g of carbohydrates for S, 25 g for M, and 50 g for L). In some embodiments, the blood glucose data and / or pen cap wear information may be analyzed to adjust the user's dosage parameters and / or meal-based dosing recommendations. In some embodiments, the blood glucose data and / or pen cap wear information may be analyzed to suggest to a medical professional or user changes to the user's dosage parameters and / or meal-based dosing recommendations.

[0031] In some embodiments, accessories provided herein (e.g., pen caps) may provide meal-based bolus recommendations based on time of day and / or meal category. For example, in some embodiments, the pen cap may provide different meal-based bolus recommendations based on breakfast time (e.g., around 8:00 AM), lunch time (e.g., around noon), or dinner time (e.g., around 6:00 PM). In some embodiments, the pen cap may provide different meal-based bolus recommendations for different meal categories, meal preferences, or past meal statistics, such as large (L), medium (M), small (S), etc., which may be based on the carbohydrate count or glycemic impact of the meal estimated or specified by the user. For example, for each treatment recommendation, the user may obtain recommended meal-based boluses for the S meal, the M meal, and the L meal. In some embodiments, the user may press a button or user-selectable icon to request recommendations for the S meal, the M meal, and the L meal. In some cases, the meal-based bolus recommendations for each meal category (S, M, and L) may change based on the time of day. In some embodiments, the meal-based bolus recommendations for each meal category (S, M, and L) may vary based on the user's past assessment and / or consistency of meal sizes. In some embodiments, a single display can show different recommended insulin doses based on different meal characteristics and / or display a range of doses based on the user's typical meal sizes (e.g., customized to the user's meal sizes based on past data), which may be based on time of day, day of the week, date, the user's location, or any other collected data.

[0032] In some embodiments, the systems provided herein can include one, two, or more connected pen caps for insulin pens or other accessories for insulin pens (e.g., connected dose-capture insulin pen caps), continuous glucose monitoring systems (CGMs) (or flash glucose monitoring systems), mobile applications, alert accessories, and / or critical web service cloud software. In some embodiments, connection to a cloud-based server can allow for storage of data for use by the system when needed and transfer of information to other devices outside the system (e.g., optional secondary display of data, reports). In some embodiments, the components of the systems provided herein can be connected wirelessly or can be connected wirelessly using any of Bluetooth Low Energy (BLE), 433 MHz Ultra High Frequency (UHF) radio, and / or Near Field Communication (NFC) protocols.

[0033] One or more embodiments of the present disclosure may include an insulin delivery system including an insulin delivery device, a user interface adapted to be secured (releasably or non-releasably) on or to the insulin delivery device, a memory for storing one or more user-specific dosage parameters, and one or more processors adapted to communicate with the memory, receive blood glucose data, identify recommended insulin dosages, and / or identify estimates of insulin administered using the insulin delivery device. The user interface may display one or more recommended insulin dosages at least in part using the blood glucose data and / or previous estimates of administered insulin, data related to previous insulin dosages (e.g., IOB characteristics associated with each user-selectable icon or button based on at least one of the user-specific dosage parameters). The processor may be adapted to update meal characteristics associated with each user-selectable icon or button based on the blood glucose data.

[0034] In accordance with one or more devices, systems, or methods of the present disclosure, a system or method may include a glucose monitor that can provide blood glucose data via one or more communication (e.g., wireless communication) technologies. In some embodiments, the glucose monitor of the systems or methods provided herein can use multiple wireless communication technologies to transmit blood glucose data. For example, the glucose monitor can include a flash near-field communication circuit and a wireless communicator. In some embodiments, the systems and methods provided herein can have one or more insulin pens or pen accessories receive blood glucose data from the glucose monitor via a first communication technology (e.g., NFC) and another device (e.g., a mobile device) receive data from the glucose monitor and / or insulin pen via a second communication technology (e.g., BLE or UHF). In some embodiments, a smart pen or pen accessory in the methods and systems provided herein can communicate with the serial and / or glucose monitor of the methods and systems provided herein only within a first range, and the mobile device can be adapted to passively receive data whenever it is within a second range greater than the first range. In some embodiments, a smart pen or pen accessory provided herein may be configured to receive data only when a user chooses to take an action to receive the data (e.g., pressing an "activate" button and / or bringing the pen or pen accessory into close proximity to a glucose monitor), while another device (e.g., an associated mobile device) may be adapted to passively receive the data regardless of user action as long as it is within a range specified by the communication method or link.

[0035] In accordance with one or more devices, systems, or methods of the present disclosure, the user interface on a smart insulin delivery device or accessory may therefore include one or more user-selectable buttons or icons. In some embodiments, a user-selectable button or icon may be used to activate a smart pen or smart pen accessory to receive blood glucose data from a blood glucose monitoring / sensor system (e.g., including a CGM, BGM, flash glucose monitor, etc.). In some embodiments, a user-selectable button or icon may be used to activate a display on the smart pen or pen accessory to display a recommended insulin dose for insulin in an insulin pen secured to the smart pen or pen accessory. In some embodiments, a user-selectable button or icon may be used to switch the display between different displays. In some embodiments, a single user-selectable button or icon may be used to activate a smart pen or pen accessory to receive blood glucose data and to activate a display, which then displays a recommended insulin dose on the smart pen or pen accessory receiving the blood glucose data. In accordance with one or more devices, systems, or methods of the present disclosure, the processor may determine a rapid-acting insulin dosage recommendation based on factors selected from the number of carbohydrates divided by the PWD's carbohydrate-to-insulin ratio, the difference between the current blood glucose level and the target blood glucose level divided by the PWD's insulin sensitivity factor, a reading from a blood glucose monitor (BGM), data from a continuous glucose monitor (CGM), blood glucose trend data, remaining insulin (IOB) data, remaining carbohydrates (COB), whether the PWD is exercising or plans to exercise, whether the PWD is ill, whether the PWD is pregnant, whether the PWD is menstruating, and whether the PWD has consumed a particular medication.

[0036] In some embodiments, a reusable smart pen may include a dosage detector, a reusable chamber, one or more insulin cartridges, and a manual delivery mechanism, wherein the detector may be configured to detect a first insulin delivery event associated with the manual delivery mechanism.

[0037] System architecture of the treatment management system 1 shows an insulin therapy management system 10 (sometimes referred to as a diabetes management system) that includes an analyte sensor system 101, a first accessory 102, a second accessory 103, and a mobile application 104. The therapy management system 10 may include one or more web services 105 that communicate with the mobile application 104 over a network 108. The first accessory 102 and the second accessory 103 are two of many accessories that may join and leave the insulin therapy management system 10 and serve to assist a user with manual insulin delivery.

[0038] Although aspects of embodiments of the present disclosure are described with respect to accessories and caps, those skilled in the art will appreciate that many of the features may be implemented in electronics packages (i.e., smart electronics) that may be integrated with an insulin delivery device, attachable to an insulin delivery device, attachable to an insulin container, etc., all as specifically contemplated by the inventors of the present disclosure.

[0039] The first accessory 102 and the second accessory 103 may be configured to capture information regarding the delivery of insulin by the manual delivery device 106 and the manual delivery device 107, and in various embodiments may include internal sensors for dose capture, a user interface for displaying information and receiving user input, and other interfaces for wireless or wired communication with one or more of the manual delivery device 106, the manual delivery device 107, the mobile application 104, the analyte sensor system 101, and the mobile application 104.

[0040] The mobile application 104 may execute on any suitable mobile computing device capable of storing and executing a mobile application adapted to display and input therapy-related information wirelessly received from other components of the system and from a graphical user interface that allows the user to interact with the application. In one embodiment, the mobile device may also store and execute the trusted mobile application within a trusted execution environment (hardware and / or software) that is generally inaccessible to users or devices communicating with the mobile device 140, but is accessible to other applications executing on the mobile device 140. Various functions and calculations related to the therapy management system, including alerts and recommendations presented to the user, may be performed in part or in whole by the trusted mobile application. Furthermore, communication with insulin pens, pen caps, glucose sensors, and other accessories may be limited in part or in whole to the trusted mobile application.

[0041] In general, embodiments of the present disclosure may use any suitable wireless communication protocol for communication between the accessory, the manual delivery device, the glucose sensor, and the mobile device. Examples of suitable wireless communication protocols include short-range wireless communication (ISO / IEC 14443 and 18092 compliant technologies), wireless modems and routers (IEEE 802.11 compliant technologies), and Bluetooth® / Bluetooth Low Energy (BLE) (IEEE 802.15 compliant technologies).

[0042] The glucose sensor system 101 may be any suitable glucose sensor system 101, such as a blood glucose monitor (BGM) and flash glucose monitor adapted to determine blood glucose levels using blood glucose test strips, or a continuous glucose monitor (CGM). In some cases, the glucose sensor system 101 can function as both a flash glucose monitor and a continuous glucose monitor by enabling both intermittent and on-demand transmission of blood glucose data. In some embodiments, the glucose sensor system 101 can wirelessly transmit data when interrogated by a reader device (e.g., using NFC communication). In some embodiments, the glucose sensor can wirelessly transmit data at predetermined intervals (e.g., using radio frequency) using any suitable communication standard (e.g., Bluetooth Low Energy (BLE)). In some cases, the systems and methods provided herein may include multiple glucose sensor systems (e.g., continuous or flash glucose monitors and blood glucose meters).

[0043] In some embodiments, the accessories may be associated with a particular type of insulin, for example, a first accessory 102 is associated with long-acting insulin delivery and a second accessory 103 is associated with fast-acting insulin delivery.

[0044] In some embodiments, the glucose sensor system 101 can transmit glucose data using multiple communication technologies. In some embodiments, the mobile application 104 and / or one or more of the manual delivery devices 106, 107 or accessories 102, 103 can include an NFC reader adapted to obtain blood glucose data from the glucose sensor system 101 when brought within interrogation distance of the glucose sensor system 101. In some embodiments, the mobile application 104 and / or one or more of the manual delivery devices 106, 107 or accessories 102, 103 can wirelessly receive blood glucose data from the glucose sensor system 101, which is broadcast at predetermined intervals (e.g., every 30 seconds, every minute, every 2 minutes, every 3 minutes, every 5 minutes, every 10 minutes, every 15 minutes, etc.).

[0045] In a polling (or query) mode of operation, the glucose sensor system 101 can wirelessly transmit blood glucose data corresponding to a past period of time to one or more of the accessories 102, 103 and the mobile application 104. For example, when a first accessory 102 queries the sensor system 101, it may receive stored glucose data from the past 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, etc. In some cases, the broadcast blood glucose data may include only current or more recent blood glucose values. For example, in some cases, the blood glucose data received at the mobile application 104 directly from the glucose sensor system 101 may include only the most recent readings (e.g., from the last 10 minutes), which may be used by the mobile application 104 to issue warnings or alerts based on the most recent blood glucose data.

[0046] The accessories 102, 103 may include one or more processors and memory for controlling wireless communication, for controlling a wireless communication interface, for controlling a user interface, and / or for determining treatment recommendations.

[0047] In some embodiments, an application running on the accessory 102, 103 may execute one or more algorithms to determine an estimated glucose value (EGV) from the raw glucose sensor data. In some embodiments, the glucose sensor system 101 may transmit the EGV to the accessory. In some embodiments, the accessory and / or smart electronics provided herein may include a memory that stores user-specific dosage parameters (e.g., recommended daily dose or total daily basal dose (TDBD) of long-acting insulin, insulin sensitivity factor (ISF), carbohydrate-to-insulin ratio (CR), correction amount based on blood glucose range, total daily insulin dose (TDD), target glucose value, recommended rapid-acting doses for different meal sizes or categories, etc.). In some embodiments, the user-specific dosage parameters may be time-of-day dependent, such as time-of-day dependent CR and ISF values. In some embodiments, the accessory 102, 103 provided herein may have a memory that stores recommended doses of rapid-acting insulin for different meals or different meal categories. In some embodiments, user-specific dosage parameters and / or different recommended dosage amounts for different meals may be updated via a mobile application 104 that wirelessly communicates with the accessory. For example, an algorithm in the mobile computing device or in the cloud may update these parameters or recommended dosage amounts. In some embodiments, the parameters or recommended dosage amounts may be updated by a medical professional or manually by the PWD or caregiver. In some embodiments, the accessory may include an algorithm in memory that is executed by a processor to automatically update user-specific dosage parameters or recommended dosage amounts.

[0048] In some embodiments, the accessories 102, 103 provided herein can display or otherwise inform the user of current blood glucose levels and / or blood glucose trend data (e.g., rate of change) based on the glucose data received from the glucose sensor system 101, and the accessories 102, 103 provided herein (or other smart electronics) may provide recommended insulin dosages based on one of the blood glucose data, user-specific dosage parameters, recommended dosages set by the user or a medical professional, time of day, meal data or categories, or any other suitable input.

[0049] While the system 10 is described with two accessories 102, 103, it is not limited to this and may include more or fewer accessories. For example, the accessory 102 may include a pairing or discoverable mode that broadcasts information discoverable by the mobile application 104. The broadcast may be via Bluetooth beacon or other suitable communication protocol. In response to a pairing confirmation, such as by holding the accessory 102 and a mobile device hosting the mobile application 104 close together or by pressing a button on either the accessory 102 or the mobile application 104 for a sufficient period of time, the mobile application 104 may create a profile of the manual delivery device associated with the accessory 102. In one embodiment, the accessory 102 may be specifically calibrated for a particular type of manual delivery device and may provide the mobile application 104 with an identifier for the delivery device type. In another embodiment, once the accessory 102 and mobile application 104 are paired, setup information may be provided in the mobile application 104 or the accessory's interface.

[0050] In one embodiment, pairing may also include sharing an encryption key that the devices can use to decrypt / authenticate messages from devices in system 10 .

[0051] Each accessory paired with the system 10 may have a profile created by the mobile application 104. In one embodiment, the mobile application 104 may query the web service 105 to see if a device profile already exists for the user, and if so, may request that it be sent. This may allow the mobile application 104 to avoid duplicate setup and may allow the recommendation algorithm running on the mobile application 104 to utilize more of the user's historical data or physiological attributes (e.g., insulin sensitivity) refined by actual glucose measurements and glycemic response analysis.

[0052] Once a profile is created, the mobile application 104 may use the profile to store insulin therapy-related settings, which may include user-specific dosage parameters, device delivery characteristics, and specific techniques that may be used to identify recommendations for the user.

[0053] In one embodiment, each manual delivery device profile may include or be part of a user profile that includes preset correction doses for specific blood glucose ranges. In one embodiment, the preset doses may be entered in the mobile application 104. In another embodiment, the preset doses may be entered in one of the web services 105 (e.g., by a healthcare provider or parent) and downloaded to the mobile application 104.

[0054] As described in more detail below, in one embodiment, a user may select from available doses, and the system monitors dosing activity on an associated manual delivery device. As described more fully herein, dosing activity may be specifically detected (e.g., by detecting medication exiting the needle of the delivery device) or inferred (e.g., using capping information). In some cases, a correction dose may not be available for a period of time after insulin administration or for a detected possible dose. For example, the methods, systems, and devices provided herein may detect a dose or a possible dose, but may not be able to identify the dose, and therefore, such systems, methods, and devices may not be able to identify the amount of active insulin (e.g., IOB) remaining in the user. Accordingly, such systems may prevent calculation or suggestion of a correction dose for a period of time (e.g., at least 2 hours, at least 3 hours, at least 4 hours, or at least 5 hours) after a previously detected dose or a detected possible dose of rapid-acting insulin.

[0055] Since meal dosage recommendations may be calculated for manual delivery devices with rapid-acting insulin, the profile may also include or reference an algorithm that calculates meal dosages to offset the effects of large, medium, or small meals on blood glucose levels. In one embodiment, the algorithm may be initially tuned to the user using physiological information about the user and personalized over time using actual glucose sensor data and administration event information.

[0056] The mobile application 104 is configured to record past treatment-related information, such as blood glucose history, dosages, medications administered, and administration timing information.

[0057] The system 10 is also configured to allow accessories to be removed. For example, in a setup screen of the mobile application 104, a user may select the manual delivery device 107 to be removed / unpaired from the system 10. In response to the selection, the manual delivery device 107 may initiate a confirmation prompt to the user. In one embodiment, a confirmation process including a specific user action (e.g., pressing and holding a button on the mobile device and a button on the accessory 104) may be used to confirm the removal. In response to the confirmation, a device profile may be stored, and the accessory 103 may change to an unrelated state and power down.

[0058] System 10 is also configured to add and remove glucose sensor system 101 and other glucose monitoring devices configured to transmit blood glucose data. For example, as described below, a communication link between accessory 103 and glucose sensor system 101 may be initiated by swiping or shaking accessory 103 in proximity to glucose sensor system 101. In one embodiment, the communication link may be initiated according to a near-field communication (NFC) protocol in which an antenna and reader IC on the accessory interrogates a tag (typically a chip) on glucose sensor system 101. Membership / activation data may be shared between systems so that other devices (e.g., accessories, mobile devices) may access blood glucose data at glucose sensor system 101.

[0059] Background Activity and Synchronization If the required devices are available and online, the following activities may be performed in the background. These activities are described in the workflow below and may change based on system status. In the following description, the first accessory 102 is associated with long-acting insulin delivery and the second accessory 103 is associated with rapid-acting insulin delivery.

[0060] Execution of a program on the first accessory associated with long-acting insulin delivery In one embodiment, the first accessory 102 or a device in communication with the first accessory 102 may execute software to calculate the user's long-acting insulin dosage needs. In one embodiment, the glucose measurements are transmitted to a long-acting insulin dosage recommendation service hosted in the cloud. In various embodiments, the glucose values ​​may be transmitted to a cloud service (e.g., via a wireless or cellular connection) at regular intervals, as described in the workflow above, resulting in updates to the treatment parameters. In one embodiment, the pen cap 112 may include a wireless or cellular device and may transmit the glucose values ​​to the cloud service via a wireless or cellular connection. In another embodiment, the first accessory 102 may piggyback on the wireless or cellular connection of the mobile device on which the mobile application 104 runs. The first accessory 102 periodically backs up data to the cloud via the mobile application 104 (e.g., via a local connection such as a Bluetooth or BLE connection).

[0061] The first accessory 102 may receive updated treatment parameters from the cloud service 105 when they are authorized and available. An example data flow is described below.

[0062] Execution of a program on a second accessory associated with rapid-acting insulin delivery In one embodiment, the second accessory 103 associated with rapid-acting insulin delivery, or a device in communication with the second accessory 103, executes software containing an algorithm to calculate the user's required rapid-acting insulin dosage. The glucose values ​​and meal selections may also be transmitted (e.g., via a wireless or cellular connection) to a rapid-acting insulin dosage recommendation service at regular intervals, as described in the workflow above, so that calculations can be made. In one embodiment, the second accessory 103 may include a wireless or cellular device and may transmit the glucose values ​​to a cloud service via a wireless or cellular connection. In another embodiment, the second accessory 103 may piggyback on the wireless or cellular connection of a mobile device on which the mobile application 104 is installed and running. The second accessory 103 periodically backs up data to the cloud via the mobile application 104 (e.g., via a local connection such as a Bluetooth or BLE connection).

[0063] The second accessory 103 receives updated treatment parameters from the cloud services when they are authorized and available. This data flow is discussed in a later section.

[0064] Running a program in a mobile app The mobile application 104 may act as a conduit for information, running in the background and synchronizing with the BLE devices (e.g., the first and second accessories 102 and 103, the glucose sensor system 101) and the cloud. Information is synchronized periodically as described above. Additionally, system status configuration, dosage history, and glucose trends and predictions may be displayed as they are calculated in the cloud and pushed to the mobile application 104.

[0065] Treatment parameter updates 1A, the cloud service may run algorithms to update and individualize the user's treatment parameters (ISF, CR, TDBD, glucose target, correction chart, meal category dose) over time based on information provided by local systems (e.g., to the cloud). These values ​​may be updated as data is pushed from accessories 102, 103 to the cloud via the PWD's mobile application 104. In one embodiment, when new values ​​are ready to be pushed to the user's mobile application 104, they may first be pushed (e.g., via a wireless or cellular connection) to the healthcare provider's (HCP) web portal for approval.

[0066] In some cases, the portal may alert the HCP that a new set of parameters is ready to be reviewed. The clinician may then review the values ​​and approve or reject them. If rejected, the cloud service is notified and no other action occurs.

[0067] If approved, the cloud service 105 is notified and the value (e.g., the updated parameter) is pushed to the user's mobile application 104 (e.g., via one of the system's local devices, such as the accessories 102, 103 and / or a mobile application running on a mobile device) for approval. For example, the value may be sent to the mobile application, which then locally communicates the value to one or both of the accessories 102, 103.

[0068] In some cases, the algorithm may determine whether an update is suggested and send a notification to the user suggesting that the user update the user's treatment parameters (perhaps in consultation with the user's physician).

[0069] 14 illustrates an exemplary process for updating therapy information according to an embodiment of the present disclosure. In operation 502, a user accesses therapy settings using the mobile application 104. The therapy settings may be stored in the mobile application 104, the accessories 102, 103, or both. In operation 504, new therapy settings are provided by the mobile application 104 via a user interface configured to receive the new settings. In operation 506, the mobile application 104 may present a notification in the user interface indicating that the settings need to be synchronized to the accessories 102, 103. In operations 508 and 510, the mobile application 104 may wirelessly communicate one or more of the new settings to the accessories 102, 103. In one embodiment, therapy settings associated with long-acting insulin delivery are sent to the accessory associated with long-acting insulin delivery, and therapy settings associated with rapid-acting insulin delivery are sent to the accessory associated with the settings and transmitted to the accessory associated with rapid-acting insulin delivery.

[0070] Pen Cap and Insulin Pen System Architecture In use, the therapy management system 10 may assist the PWD (or their caregiver) in identifying the time and amount of insulin to inject. The system 10 may be configured to provide recommendations to assist the PWD (or caregiver) in identifying appropriate insulin doses based on current data from a glucose sensor, based on stored therapy parameters, and / or based on data related to insulin infusions. In some embodiments, the accessories 102, 103 are configured to collect and provide data related to insulin infusion events.

[0071] 1B and 1C can be insulin pens, such as commercially available mechanical insulin pens that contain any suitable insulin, for example, long-acting insulin and fast-acting insulin (sometimes referred to as rapid-acting insulin or ultrafast-acting insulin). Suitable fast-acting insulins include HUMALOG®, NOVOLOG®, APIDRA®, and FIASP®. Suitable long-acting insulins include LANTUS®, LEVEMIR®, TOUJEO®, and TRESIBA®.

[0072] 1B and 1C, the manual delivery device 107 may be a long-acting insulin injection pen 110, and the manual delivery device 106 may be a rapid-acting insulin injection pen 120. FIG. 1B illustrates an insulin therapy management system 11, an insulin pen 110, an insulin pen 120, a GCM 130, and a mobile device 140 having a therapy management mobile application running thereon. The first accessory 102 may be a pen cap 112, and the second accessory 103 may be a pen cap 122. FIG. 1B illustrates an insulin therapy management system 12, an insulin pen 110 with a pen cap 112, an insulin pen 120 with a pen cap 122, a GCM 130, a BGM 150, and a mobile device 140 having a therapy management mobile application running thereon. As shown, the system 12 has the components of the system 11, but includes a BGM 150 and a different mobile application display for blood glucose levels.

[0073] The insulin pens 110, 120 may include a dial (not shown) that can be used to configure the pen to inject a dose of insulin corresponding to a rotation of the dial. In some embodiments, each insulin injection pen may be a reusable insulin pen that includes a display or audio and / or input device, such as those disclosed for the pen caps disclosed herein. An example of a reusable insulin pen is an insulin pen that includes a chamber for removing a used insulin cartridge and loading a new insulin cartridge. The insulin pens 110, 120 may include an interface for wireless and / or wired communication with one or more of a pen cap, a glucose sensor, a mobile device, and other accessories.

[0074] The pen cap attachment information (i.e., information regarding when the pen cap is secured to and / or released from the injection pen (also referred to herein as "capping" and "uncapping," respectively)) may include information regarding the current capping period (e.g., time since last capping), information regarding one or more capping detachment periods, and the timing (e.g., time of day or elapsed time) of each capping detachment and each capping. In some embodiments, the pen cap attachment information may be displayed to the user on an interface in the pen cap. In some embodiments, the pen cap attachment information may be announced by a speaker within the pen cap. For example, in some embodiments, the pen cap may provide a timer that counts up (or counts down) since the pen cap was last secured to the injection pen. In some embodiments, the pen cap may wirelessly communicate the pen cap attachment information to a mobile device 140 (e.g., a smartphone, tablet, etc. running a mobile application).

[0075] The pen cap wear information may be used to tailor the user experience. In some embodiments, the pen cap tailors the presentation of treatment-related information and / or recommendations provided to the user in response to the pen cap wear information. For example, in some embodiments, the pen cap may provide a bolus recommendation to correct an elevated blood glucose level based on data from the CGM 130, but the presentation of such a correction bolus recommendation may be limited to periods when the current pen cap wear period is longer than a threshold period (e.g., at least 3 hours, at least 4 hours, or at least 5 hours). In some embodiments, the pen caps 112 and 122 may provide notifications, alerts, and / or warnings to the user based on the pen cap wear information (e.g., based on the period the pen cap has been worn and / or removed). For example, if the pen caps 112 and 122 are removed from the injection pen within a threshold period of time (e.g., within 30 minutes or 1 hour for rapid-acting insulin, or within 6-12 hours for long-acting insulin) of previous cap placement, the pen cap may provide a visual, audible, and / or tactile notification that the user may have recently used the pen to administer insulin. In some embodiments, the pen caps 112 and 122 may wirelessly communicate with the mobile computing device 140, and one or more notifications, alerts, or warnings based on the pen cap placement information may be announced or displayed on the mobile computing device.

[0076] The capping sensor for detecting possible capping, uncapping, and re-capping events may be an analog or digital electronic sensor integrated into the pen cap, or more generally, an accessory, that responds to its attachment or detachment from the insulin pen. In one embodiment, it may incorporate a piezoelectric material that generates a small current when pressure is applied (e.g., by being firmly secured to the insulin pen). In another embodiment, it may respond to relative motion between itself and a small magnetic element secured to the medication delivery device. In yet another embodiment, it may respond to open and closed circuits (e.g., an open loop when the cap is removed and a closed loop when the cap is attached). Any suitable sensor for detecting capping and uncapping may be used.

[0077] Cap on / cap off events and administration events The pen cap wear information may be stored, displayed, and analyzed in combination with glucose data to determine, for example, whether a person is properly administering insulin for a meal and / or to correct elevated blood glucose levels. In some embodiments, the pen cap wear information may be presented to the user on a graphical display of the user's blood glucose data and / or to a medical professional. In some embodiments, blood glucose data from the period after each cap wear event may be evaluated to determine whether the user properly administered, under-administered, or over-administered insulin for that cap wear event.

[0078] In some embodiments, a pen cap removal, pen cap installation, or pen cap re-installation event may be ignored if other information indicates that no dose was administered, for example, if no change in the insulin pen dose selection (e.g., dial) is detected, the event may be ignored.

[0079] In one embodiment, the pen cap 112, 122 may be configured to track a pen cap on event, which may be used to infer a dosing action. In various embodiments, the system 11 and / or 12 may be configured to infer that a cap on event corresponds to a dosing action and record (e.g., as a dosing event) one or more of the time, the type of insulin, and the amount of insulin delivered. In one embodiment, the amount of delivered insulin may be captured by the insulin pen 110, 120 and provided to the pen caps 112 and 122. In some embodiments, the pen caps 112, 122 may identify and track the remaining insulin in the insulin pen 110, 120 based on each dose. In another embodiment, the pen caps 112, 122 may track the amount of insulin remaining in the insulin cartridge and, based on changes in the amount of insulin in the insulin cartridge, identify the amount of insulin associated with a dosing action. In additional embodiments, the smart pen or pen accessory may detect the set or administered dose using other suitable techniques.

[0080] In some embodiments, the pen cap 112, 122 may include one or more of the following: a smart sensor that detects substances on the user's finger, such as a temperature sensor that determines whether the insulin needs to be replaced or is faulty (e.g., along with blood glucose data), a touchscreen, and a capacitive touch button. For example, the mobile application or one or more of the pen caps 112, 122 may include a temperature monitor that monitors one of an average temperature, a high temperature, or a low temperature experienced by the pen cap 112, 122. Such temperature ranges and / or minimum and maximum temperatures may be attributable to a therapy (e.g., insulin) attached to the pen cap 112, 122. Upon exposure to a minimum and / or maximum temperature (e.g., or for a selected period of time within a selected temperature range), the pen cap 112, 122 may provide an alert and / or warning to the user indicating that the insulin has been exposed to an out-of-range temperature (e.g., a level that exceeds user and / or insulin storage recommendations).

[0081] In some embodiments, such a temperature sensor may be used in conjunction with a blood glucose sensor that indicates that the insulin is not having the expected effect on the subject's blood glucose levels when exposed to a selected temperature level. For example, if the insulin is exposed to an out-of-range temperature and data from the blood glucose monitor indicates that the insulin is not having the expected effect on the subject's blood glucose levels (e.g., a smaller or larger than expected change), a warning and / or alert may be provided. In some cases, the methods, systems, and devices provided herein may tailor notifications regarding temperature exposure based on additional data indicating that insulin effectiveness is or may be impaired to alleviate notification fatigue for users experiencing notification fatigue. In some embodiments, the mobile application or pen cap 112, 122 may trigger a reminder to the user to take a post-infusion reading to determine the effectiveness of the insulin recently provided to the subject.

[0082] In some embodiments, the mobile application or pen cap 112, 122 can communicate with a wearable device (e.g., a smartwatch) worn by the PWD to determine an activity being performed by the subject (e.g., whether the subject is eating). For example, the wearable application may run on a wearable device that allows the user to interface with one or more of the pen cap 112, 122, insulin pen 110, 120, mobile device 140, and other accessories. In some embodiments, the wearable application may interface with a mobile application running on the mobile device 140, such as mobile application 104. The mobile application may perform processing for various features described herein, and the wearable application may provide alerts and recommendations to the user and provide information received from the user at the wearable device, such as instructions for meals, exercise, or medication actions, to the mobile application.

[0083] Swipe / Collect glucose information Figure 2 illustrates a PWD that uses one or more portions of the diabetes management system 10 of Figure 1. As shown in Figure 2, the PWD 20 can have, for example, a glucose sensor system 101 applied to the arm to detect the PWD's blood glucose level, and a user can interrogate the glucose sensor system 101 using a pen cap 122 secured to a rapid-acting insulin pen 120. Before and after the user swipes the pen cap 122 of Figure 2, the pen cap 122 can display treatment-related information.

[0084] FIG. 3 shows a display on a pen cap. As shown in FIG. 3, for example, a display 124 on a pen cap 122 can show the time 125 (e.g., the time and / or date of the last dose) of the most recent dose, or "last dose," which can help a user remember whether they have bolused for a recent meal and can help the user avoid unintentionally stacking boluses. In some embodiments, such as with a pen cap capable of detecting doses, the display can also show the number of units of the last dose. In some embodiments, the timing of the last dose can be a clock that increments to show how long ago the last dose was administered. In some embodiments, the display can show the most recently obtained blood glucose level and the time of acquisition. In some embodiments, the display can be a bi-stable display, such as an electronic paper display. An electronic paper display is a display that mimics the appearance of regular ink on paper. In some embodiments, the display can include identification information (e.g., a label identifying the user, such as "Sarah's Pen") and / or information about the type of insulin pen to which the pen cap is attached (e.g., the brand of insulin, whether the insulin is rapid-acting or long-acting, etc.). As shown, the pen cap 122 may include a button 123, which may be used to activate the pen cap (change modes), switch screens, and / or provide other functions.

[0085] 4 shows the pen cap 122 displaying blood glucose data 129, which may include a current blood glucose level and a trend arrow. The blood glucose level may be received from the glucose sensor system 101 after scanning the pen cap 122, as shown in FIG. 2. In some embodiments, placing the pen cap 122 in proximity to the glucose sensor system 101 (e.g., scanning the sensor 130) may act to wake the pen cap 122 from an idle mode. In some cases, a push button 123 may wake the pen cap 122 to enable scanning of the glucose sensor system 101. In some cases, removing the pen cap 122 from the pen 120 may wake the pen cap 122 to enable scanning of the glucose sensor system 101.

[0086] Immediate service recommendation In one embodiment, system 11 and / or system 12 may be configured to provide a correction dose recommendation and present the recommendation in a user interface. Referring to FIG. 4 , the display of pen cap 122 includes a recommended correction dose 127d and a corresponding correction dose icon 126d. If the user's glucose concentration is within an acceptable range, pen cap 112 may respond to the recommendation system by displaying information indicating that a correction dose is not necessary. In some embodiments, further input may be entered or requested by the user, such as, for example, an indication of a meal for the user to select (e.g., where pen cap 112 may then display multiple meal options, as described below). In some cases, button 123 may be progressively pressed to increase meal size, incrementally display larger meal sizes, and / or highlight different meal sizes. The dosage for the meal, and any correction doses, if necessary, may be provided to the user along with an indication of the meal size. The indication of meal size may be based on the size of the icon, the number of carbohydrates displayed, and / or the label (e.g., large or L, medium or M, small or S). In other embodiments, the meal indicator or icon may be based on other characteristics of the meal, such as, for example, a preferred meal selection made by the user, meals having selected nutritional characteristics (e.g., carbohydrates), or specific meals based on the time of day (e.g., breakfast, lunch, dinner, snack).

[0087] Because changes in blood glucose levels depend on factors such as basal metabolism, diet, and exercise, the recommended correction dose may only be valid for a set period of time. In one embodiment, the pen cap 122 may be configured to display the recommended correction dose for a set period of time (e.g., the period since the last scan event, as shown in FIG. 2). The set time may be user-defined or may be specified based on a confidence level corresponding to the timing of the recommendation and the user's physiological factors. Thus, the recommended correction dose may have an associated confidence level and a "decline rate" for that confidence level. After a timer expires (e.g., within the last 5, 10, 15, 20, 30, or more minutes), the pen cap 122 may stop and display the recommended correction dose. In some cases, the pen cap 122 may stop displaying the recommended correction dose if the received glucose value expires (e.g., more than 10, 15, 20, or 30 minutes have passed). In various embodiments, the glucose data transmitted from glucose sensor system 101 to pen cap 122 in a single transmission can include data that can be used by the pen cap to determine at least two estimated glucose values ​​(EGVs) over a period of at least 30 minutes. In some embodiments, a single transmission can include at least 1 hour of glucose data, at least 2 hours of glucose data, at least 4 hours of glucose data, at least 6 hours of glucose data, or at least 8 hours of glucose data. For example, a CGM and / or flash glucose monitor, such as glucose monitor 130, can transmit multiple hours of glucose data in a single transmission event.

[0088] In one embodiment, in response to the timer expiring, the display 124 on the pen cap 122 may indicate to the user that a new blood glucose reading is required before an updated recommendation based on the blood glucose data can be made. In some cases, a pen cap without current blood glucose data may provide a recommendation based solely on meal size, but may optionally further include an indication that the recommendation does not include a correction component.

[0089] In one embodiment, a correction dose may only be displayed if a current blood glucose value is available (e.g., a valid blood glucose value from the previous 10 minutes, 15 minutes, or 30 minutes). If a valid blood glucose value is not available, a message may be displayed to the user that a current blood glucose value is needed.

[0090] FIG. 5 shows pen cap 122 with meal-related dosage recommendations (referred to herein as “meal recommendations”) 127a-127c that may be displayed for different sized meals identified by meal icons 126a-126c. For example, a user may obtain meal recommendations after pressing button 123 during use and viewing the screen of FIG. 4. In some embodiments, the meal recommendations may be based on meal dosages set by a medical professional, PWD, and / or caregiver using a mobile application during setup or upon update by the medical professional, PWD, and / or caregiver. In some embodiments, the meal recommendations may be based on user-specific dosage parameters that are automatically updated by the system using any suitable algorithm for updating dosage parameters. In some embodiments, if the user has recently taken a blood glucose reading (e.g., within the last 5, 10, 15, 20, 30, or more minutes), the meal recommendations 127a-127c may include both meal dosages and correction dosages. In some embodiments, the meal recommendations 127a-127c may include only meal dosages, and the pen cap 122 may not require the user to scan a glucose sensor to receive the meal recommendations 127a-127c.

[0091] In some embodiments, the pen cap 112 may decline to provide a correction dose for a predetermined period of time after the previous administration and / or for a period of time after the previous administration based on an identification of the amount of active insulin (e.g., IOB) in the PWD. In some cases, the correction dose may be adjusted based on an estimate of active insulin (e.g., an IOB estimate). In some cases, the IOB may not be known, but an estimated percentage of remaining active substance from the previous administration may be identified and displayed to the user. In some cases, the correction dose calculation may be reduced based on the estimated percentage of remaining active insulin being within a predetermined range (e.g., if remaining active insulin is identified as 5%-25%, the recommended correction dose may be reduced by 25-75%). For example, the pen cap 112 may continue to increase the recommended correction dose for a period of 2-4 hours after the previous administration based on the estimated percentage of active insulin in the subject.

[0092] Warning / alert thresholds for administration behavior In some embodiments, if the pen cap 122 identifies another recent administration (e.g., by detecting the act of capping the pen cap within the last three hours, the last four hours, or the last five hours) while the dose is unknown, the pen cap may refuse (e.g., initially refuse and optionally override) the addition of a correction component to prevent unintentional correction bolus stacking. In some embodiments, the meal icons 126a-126c may indicate whether the recommendation includes a correction component. In some embodiments, an additional icon or display may indicate whether a recommended correction dose is included and / or whether a recommended correction dose size is present. In some embodiments, by pressing button 123, the user may obtain a screen displaying the current blood glucose level, trend information (e.g., trend arrows), and recommended correction dose. In some embodiments, if there have been recent insulin administrations (e.g., within the last one, two, three, or four hours), a warning screen may appear next to or above the recommendation indicating that a recent administration has occurred to prevent unintentional correction bolus stacking. In some embodiments, a notification icon 128 may appear on the pen cap 122 to indicate to the user that more detailed suggestions, hints, alerts, or warnings are available to the user in a mobile application on the mobile device 140.

[0093] Recommendations specific to long-acting insulin delivery FIG. 6 illustrates a pen cap 112 that may be used with the long-acting insulin injection pen 110. In some embodiments, the caps 112 and 122 may share one or more (e.g., most, all) operational characteristics. As shown in FIGS. 3-6 , the pen caps 112 and 122 may have distinct visual appearances (e.g., different colors, markings, patterns, etc.) or physical structures (e.g., shapes, textures, etc.) to help the user distinguish between long-acting and rapid-acting insulin. This is because unintentionally delivering the wrong type of insulin can cause a hypoglycemic or hyperglycemic event. The pen cap 112 may include a button 113 and a display 114 (e.g., an electronic paper display). When the button 113 is pressed by the user (e.g., to activate the pen cap 112), the display 114 may remind the user (using an appropriate icon 116) about the amount of long-acting insulin 117 the PWD should inject based on stored therapy parameters (e.g., even if a blood glucose reading has not been received from an associated blood glucose sensor).

[0094] In some embodiments, if the user recently removed the pen cap 112 from the pen 110, the display may show information about the time the pen cap 112 was removed or other warning to prevent unintentional duplicate delivery of long-acting insulin. In some embodiments, the pen cap 112 may provide an audible notification to the user indicating it is time to deliver long-acting insulin based on stored therapy parameters. In some cases, methods, devices, and systems may provide a warning, alert, or notification to the user (e.g., via the pen cap or via a mobile application) if the user does not dose within a certain threshold period of the planned dose time (i.e., a "missed dose"). In some embodiments, a suitable therapy titration algorithm may suggest that the user change stored therapy parameters and / or automatically update stored therapy parameters related to the dose of long-acting insulin.

[0095] In some embodiments, the long-acting insulin pen cap 112 may use the pen cap wear information to infer a dose action. If a dose action is not inferred at a particular time or within a particular time range, the pen cap 112 may detect a missed dose of long-acting insulin. A missed dose warning, alert, and / or notification to the user may be generated and provided to the user. The missed dose notification may include information about the missed dose, such as the scheduled time and amount of long-acting insulin to be delivered.

[0096] In some embodiments, a time threshold parameter may be provided that defines the period of time since the last estimated dose action. The time threshold parameter may be configurable so that a user may set a different period of time (e.g., a value may be entered by the user or selected from a list of suggested periods in a setup screen). If the time since the last estimated dose action exceeds the time threshold parameter, a missed dose may be inferred and a missed dose warning, alert, and / or notification may be generated and provided to the user.

[0097] In some embodiments, the pen cap 112 can interrogate the glucose monitor 130 and receive glucose data and / or blood glucose data via the mobile device 140 and / or the pen cap 122. In some embodiments, the display 114 can show recent blood glucose data, the time of the data, and / or glucose trend data (e.g., trend arrows). In some cases, the pen cap 122 can be adapted not to display the current blood glucose level so that the user does not confuse the pen cap 122 with a rapid-acting pen cap 112. In some embodiments, the display 114 can include a recommended dose of long-acting insulin 117. In some cases, if a correction dose is needed, the pen cap 112 can indicate that the user should use the pen 120 to deliver a correction dose of rapid-acting insulin.

[0098] Treatment-related information In some embodiments, one or more of the pen caps 112, 122 may track and display an estimated percentage of administered doses over time. For example, the pen cap 112, 122 may track an estimated percentage of active insulin (e.g., IOB) remaining in the subject over time after each dose is administered. In some cases, the percentage IOB remaining indicator may be displayed based on the most recent time of cap wear (e.g., immediately after cap wear, the percentage IOB remaining indicator may show that the IOB remaining is 100%, but after the last cap wear, it decreases over time to zero). In some cases, the cap 112 may include a calculation of a rapid-acting insulin activity rate, which may decline over 3-6 hours. In some cases, the cap 122 may include a calculation of a long-acting insulin activity rate, which may decline over 12-36 hours. In some cases, a pen cap fitted for rapid-acting insulin may determine the percentage of intermediate-acting insulin, which may decline over 6-12 hours. In some cases, the pen caps 112 and / or 122 may be adapted to determine the amount of insulin remaining in the insulin injection pen, and therefore the dosage, and display a real-time estimate of insulin as units of insulin per insulin type.

[0099] Exemplary System Architecture FIG. 7 illustrates an exemplary communications architecture for a system (e.g., system 11 shown in FIG. 1B ), showing possible communications links between components of the system. Various components can interface with each other via controlled radio, NFC, or BLE protocols. Each of these components displays, transmits, and receives information based on the system workflow ongoing at a given time. As shown, glucose monitor 130 can communicate with fast-acting pen cap 122, communication link 231, and / or mobile device 140, communication link 232, via NFC. In some cases, a second BLE communication link 232 can be between mobile device 140 and glucose monitor 130, which can enable real-time warnings or alerts based on the current blood glucose level received by mobile device 140 via BLE communications, without requiring user interaction. In some embodiments, long-acting pen cap 112 can communicate with glucose monitor 130 via NFC communications. In some embodiments, the long-acting pen cap 112 does not communicate directly with the glucose monitor 130 via NFC (or, in some embodiments, background music via BLE), which may prevent the user from being confused by the fact that only rapid-acting insulin should be used for correction or meal administration. In some embodiments, the glucose monitor 130 may further communicate with the mobile device via a radio that transmits glucose values ​​at predetermined intervals. Both pen caps 112 and 122 may communicate with the mobile device 140 via BLE communication. Glucose data, programmed treatment parameters (e.g., daily dosage of long-acting insulin, dosages for different meal sizes (which may vary by time of day), insulin sensitivity factors, carbohydrate-to-insulin ratios, etc.), pen cap wear data (and, optionally, dosage data if detected by the pen cap) may be communicated between the mobile device 140 and each pen cap 112 and 122, and system data may be communicated to a web service 250 (which may be any remote server) via a WiFi or cellular connection 241.In some embodiments, each pen cap 112, 122 may include a processor and memory configured to execute an algorithm that identifies a recommended dosage. In some embodiments, the mobile device 140 may execute a treatment recommendation or treatment parameter update algorithm to recommend changes to and / or automatically update the programmed treatment parameters. In some embodiments, the web service 250 may execute an algorithm to recommend changes to and / or automatically update the programmed treatment parameters. In some embodiments, timing data from capping and / or uncapping events of the pen caps 112 and 122 (capping and uncapping events may individually be referred to herein as "capping events"; another event that generates capping information is a capping event, followed by a re-capping event) may be included in an algorithm to provide a treatment recommendation.

[0100] In some embodiments, initial therapy parameters may be programmed into a mobile application on the mobile device 140 and transmitted to the pen caps 112 and 122 via BLE communication links 211 and 221. In some embodiments, the pen cap 122 can use the therapy parameters received from the mobile app to recommend correction doses and meal doses. In some embodiments, the therapy parameters may include meal doses for different size meals (e.g., small, medium, and large meals). In some embodiments, the therapy parameters may include therapy parameters for correcting glucose values, such as an insulin sensitivity factor. In some embodiments, the correction may be based on a linear sliding scale correction, as described below. In some embodiments, the pen cap 112 can receive therapy parameters indicating a daily dose of long-acting insulin. In some embodiments, the pen cap 112 can receive recommended administration times for long-acting insulin from the mobile device mobile application 140 (e.g., 9:00 AM daily, 8:00 AM daily, twice daily at 8:00 AM and 8:00 PM, etc.).

[0101] Delivery of rapid-acting insulin doses When the user decides to deliver a fast-acting insulin dose (e.g., before a meal), the system can initiate the following workflow: Some actions are optional and may not be invoked if a particular device is unavailable or if the user chooses not to use them.

[0102] Taking a glucose reading A user can initiate an NFC transfer from the sensor to the Rapid Acting Insulin Smart Cap (RCap) by activating the pen cap and shaking it over the sensor, as shown in FIGS. 2 and 3.

[0103] After obtaining a glucose reading, the pen cap presents the user with the current glucose value and trend line, along with a recommended correction dose or action. If no glucose value is available within the last 10 minutes, the pen cap displays a home screen with no values, and the system proceeds to the next step in the workflow when initiated by the user. In some embodiments, the recommended correction dose may vary depending on pen cap wear information, as described elsewhere. For example, in some embodiments, a recommended correction dose for an elevated glucose reading will only be displayed if the pen cap has been on the pen for at least a threshold period (e.g., at least 2 hours, at least 3 hours, or at least 4 hours). The time of the last dose may be displayed, which is based on the most recent pen cap wear.

[0104] FIG. 8 illustrates a correction dose recommendation process according to an embodiment of the present disclosure. In operation 402, when removal of the rapid-release pen cap 122 (e.g., by a user) is detected, a recommendation mode is enabled. In one embodiment, when the pen cap 122 is then removed from the insulin pen, the pen cap 122 may change from a low-power mode to an active mode. In one embodiment, in the low-power mode, the pen cap may display information about the last dosing operation, such as the amount and / or time of the last insulin dose, as shown in FIG. 3 . In operation 404, in response to cap removal and being shaken near the glucose monitor 130, the pen cap 122 enables an intermediate mode to read a glucose measurement from the glucose monitor 130 and sends a prompt to the user to swipe the pen cap 122 near the glucose monitor 130. In one embodiment, the pen cap 122 may also enable a reader configured to interrogate the glucose monitor 130 when the pen cap 122 is in proximity. In one embodiment, the reader may be an NFC antenna that advertises itself as available for BLE communication. In one embodiment, the Bluetooth tag may be coupled to a glucose monitor 130 that may communicate with a reader in response to an advertisement. In operation 406, the glucose sensor 120, in response to the query, provides a blood glucose measurement to the pen cap 122, which decodes the received measurement. In one embodiment, the glucose measurement may be encrypted or coded using a proprietary format. In operation 408, the user presses the button 123, and the pen cap 122 enables a correction dose recommendation mode in response to the user pressing the button. In operation 410, the pen cap 122 recommends a correction dose on a display on the pen cap 122. In one embodiment, the correction dose is specified on the pen cap 122. In another embodiment, the correction dose is specified on another device, such as the mobile device 130, and communicated to the pen cap 122. In various embodiments, the pen cap 122 may be configured to alternate between a glucose reading mode and an advisory mode, allowing the user to receive a current measurement and a current recommendation.The pen cap 122 may be configured to return to a low power mode in response to a timeout.

[0105] User assessment of food effects on blood glucose (optional) If the user intends to dose for a meal, they are taken to the next screen, where three different dosage recommendations are presented for meals that will have a large, medium, or small impact on the user's blood glucose. These recommendations may change over time to adapt to the user's habits and physiology. The recommended dosages include corrections, if applicable, based on the user's glucose readings.

[0106] Inject rapid-acting insulin to capture your insulin dose The user removes the RCap from the insulin pen and attaches the needle to the insulin pen. The needle is primed, and the user then dials the desired dose and injects the insulin. The user removes the needle and replaces the cap on the rapid-acting insulin pen. The glucose value (if applicable) is sent via BLE to a mobile app, which is stored locally on the smartphone. If a connection to the cloud is available via cellular or WiFi, the data is then synchronized to the cloud. In some embodiments, a part of the system (e.g., cap, mobile application) may monitor pen use (e.g., based on data entered by the user regarding normal use of the device) to detect a priming operation (e.g., clicks, such as two sets of clicks, from the pen and / or input from the user regarding priming or lack thereof) and / or dose selection. In some cases, the methods, systems, and devices provided herein can detect the presence of a needle and infer priming behavior (i.e., considering a needle removed and replaced as priming). In some cases, the methods, systems, and devices provided herein can be considered priming based on dosage and predicted glucose impact.

[0107] FIG. 9 illustrates an injection process for a rapid-acting dose according to an embodiment of the present disclosure. In operation 422, a user launches a mobile application and inputs meal information. In operation 424, the mobile application presents one or more correction dose recommendations to the user. In one embodiment, the recommendations are based on a sliding scale of aggressiveness. In one embodiment, the recommendations may be based on a low, medium, or high glycemic impact of the meal information entered by the user. In another embodiment, the recommendations may be based on a glucose reading, and the recommendations may be based on a confidence level that the glucose reading is not too old. For example, if three recommendations are presented, the first recommendation may correspond to a high confidence level that the last glucose reading is still valid. The second recommendation may correspond to a medium confidence level that the last glucose reading is still valid. The third recommendation may correspond to a low confidence level that the last glucose reading is still valid. In operation 426, the user removes the cap from the pen cap 122, which is detected by the pen cap 122. In operation 428, the user primes the insulin injection pen 120 to deliver a dose. In operation 430, the user injects a dose of insulin from the insulin injection pen 120. In operation 432, the user replaces the pen cap 122, which is detected by the pen cap 122. In operation 434, the pen cap 122 records the dispensing action and the time of the dispensing action in response to the detected cap-on event. In operation 436, the pen cap 122 returns to a low power mode in response to the cap-on event.

[0108] Delivery of long-acting insulin doses Once the user decides to deliver a long-acting insulin dose, the system initiates the following workflow: Some steps are optional and may not be invoked if a particular device is unavailable or if the user chooses not to use them.

[0109] Taking a glucose reading A user may initiate an NFC transfer from a glucose sensor (typically a CGM) to the long-acting insulin pen cap 112 by activating the pen cap and shaking it over the sensor.

[0110] After obtaining a glucose reading, the pen cap presents the user with the current glucose value and trend line along with the recommended long-acting insulin dose. If no glucose value is available within the last 10 minutes, the pen cap will only display the long-acting insulin dose recommendation, which is adjusted to the user's habits and physiology and may change over time with the clinician's control and approval.

[0111] FIG. 10 illustrates a correction dose recommendation process according to an embodiment of the present disclosure. In operation 442, the user removes the pen cap 112 to enable the recommendation mode. When the pen cap 112 is then removed from the insulin pen, the pen cap 112 may change from the low power mode to the active mode. In one embodiment, in the low power mode, the pen cap may display information about the last long-acting insulin delivery operation, such as the amount and / or time of the last insulin delivery, as shown in FIG. 3 . In operation 444, in response to the cap being removed and shaken near the glucose monitor 130, the pen cap 112 enables an intermediate mode to read a glucose measurement from the glucose monitor 130 and sends a prompt to the user to swipe the pen cap 112 near the glucose monitor 130. In one embodiment, the pen cap 112 may also enable a reader configured to interrogate the glucose monitor 130 when the pen cap 112 is in proximity. In one embodiment, the reader may be an NFC antenna that advertises itself as available for BLE communication. In one embodiment, the Bluetooth tag may be coupled to a glucose monitor 130, which may communicate with a reader in response to an advertisement. In operation 446, the glucose monitor 130, in response to the query, provides a blood glucose measurement to the pen cap 112, which decodes the received measurement. In one embodiment, the glucose measurement may be encrypted or coded using a proprietary format. In operation 448, the user presses the button 113, and the pen cap 112 enables a correction dose recommendation mode in response to the user pressing the button. In operation 450, the pen cap 112 recommends a correction dose on a display on the pen cap 112. In one embodiment, the correction dose is specified on the pen cap 112. In another embodiment, the correction dose is specified on another device, such as the mobile device 130, and communicated to the pen cap 112. In various embodiments, the pen cap 112 may be configured to alternate between a glucose reading mode and an advisory mode, and the user may be able to receive a current measurement and a current recommendation.The pen cap 112 may be configured to return to a low power mode in response to a timeout.

[0112] Injecting an insulin dose The user removes the pen cap 112 from the insulin pen and attaches the needle to the cartridge. The needle is primed, and the user then dials the desired dose and injects the insulin. The user removes the needle and replaces the cap on the rapid-acting insulin pen. The glucose value (if applicable) is sent via BLE to the mobile app, which is stored locally on the smartphone. If a connection to the cloud is available via cellular or WiFi, the data is then synchronized to the cloud. In some embodiments, parts of the system (e.g., cap, mobile application) may monitor pen use (e.g., based on data entered by the user regarding normal use of the device) to detect a priming operation (e.g., clicks, such as two sets of clicks, from the pen and / or input from the user regarding priming or lack thereof) and / or dose selection.

[0113] FIG. 11 illustrates a process for injecting rapid-acting insulin according to an embodiment of the present disclosure. In operation 462, a user launches a mobile application and inputs meal information. In operation 464, the mobile application presents one or more correction dose recommendations to the user. In one embodiment, the recommendations are based on a sliding scale of aggressiveness. In one embodiment, the recommendations may be based on a low, medium, or high glycemic impact of the meal information entered by the user. In another embodiment, the recommendations may be based on a glucose reading, and the recommendations may be based on a confidence level that the glucose reading is not too old. For example, if three recommendations are presented, the first recommendation may correspond to a high confidence level that the last glucose reading is still valid. The second recommendation may correspond to a medium confidence level that the last glucose reading is still valid. The third recommendation may correspond to a low confidence level that the last glucose reading is still valid. In operation 466, the user removes the cap from the pen cap 112, which is detected by the pen cap 112. In operation 468, the user primes the insulin injection pen 110 to deliver a dose. In operation 470, the user injects a dose of insulin from the insulin injection pen 105. In operation 472, the user replaces the pen cap 112, which is detected by the pen cap 112. In operation 474, the pen cap 112 records the dispensing action and the time of the dispensing action in response to the detected re-cap event. In operation 476, the pen cap 112 returns to a low power mode in response to the re-cap event.

[0114] Check status with fast acting and long acting pen caps 12 illustrates a status check on the pen caps 112 and 122 in accordance with an embodiment of the present disclosure. By way of example, the status information may include the date and time of the last rapid-acting dose, a glucose trend line, the most recent glucose reading and time, and a recommended correction dose. In operation 482, the user requests a status check from the pen cap 122 related to rapid-acting insulin delivery. In operation 484, the user requests a status check from the pen cap 112 related to long-acting insulin delivery. In operation 486, the pen cap 122 may display the status information in response to the user's request. In some embodiments, the pen cap 122 may persistently display the date and time of the last rapid-acting dose when in low-power mode. In operation 488, the pen cap 112 may display the status information in response to the user's request. In some embodiments, the pen cap 112 may persistently display the date and time of the last long-acting dose when in low-power mode.

[0115] Checking System Status Users can check the system status at:

[0116] 13 illustrates a status check in a mobile application according to an embodiment of the present disclosure. By way of example, the status information may include system maintenance information (such as remaining power, remaining insulin, sensor status, etc.), the date and time of the last rapid or long-acting dose, glucose trend lines, the most recent glucose reading and time, detailed forecasts and trends, and recommended correction doses. In operation 492A, the user requests a status check from the mobile application. In operation 494A, the mobile application may display the status information in response to the user's request.

[0117] 15 illustrates a process for checking the status of a system according to an embodiment of the present disclosure. At operation 522, the mobile application 104 is launched. At operation 524, the mobile application 104 presents a user prompt, the prompt being to scan the glucose sensor system. In one embodiment, the mobile application 104 may present the prompt to check the system status in response to a request received at a user interface. At operation 526, a mobile device running the mobile application 104 is swiped near one or more glucose sensors. At operation 528, the mobile application 104 receives blood glucose data from the one or more glucose sensors. At operation 530, the mobile application 104 identifies and presents glucose data and trends, typically for a recent time window.

[0118] Mobile Application User Interface The methods and systems provided herein can further include a mobile application running on a mobile device (e.g., a smartphone or tablet) that wirelessly communicates (e.g., via BLE) with one or more pen caps described herein. In some embodiments, blood glucose data can be transmitted from the glucose sensor system 101 (e.g., from the glucose monitor 130 and / or blood glucose meter 150) either via the pen cap and / or directly from the glucose sensor system. In some embodiments, the mobile application can have a user interface that displays a graphical representation of the blood glucose data. In some embodiments, the graphical representation of the blood glucose data over time can include an indicator that conveys pen cap wear information.

[0119] FIG. 16 illustrates an exemplary display of the system (e.g., of a mobile device). For example, FIG. 16 illustrates an exemplary user interface of a mobile application including a graphical display of blood glucose data using marks (e.g., triangles, circles, wedges, or any other suitable icon or indicia of a dose) along the x-axis to indicate specific actions that may be considered insulin administration and / or other actions, such as the timing of a glucose reading, e.g., the timing of a re-capping action. In some embodiments, in the case of prolonged cap removal (e.g., if the pen cap is left uncapped for an extended period of time before being re-capped), the triangle may be wider to indicate the time over which an insulin dose is being administered. In some embodiments, the icon may be different (e.g., a different color or shape) depending on the type of insulin associated with the pen cap with the re-capping action. In some embodiments, the graphical display of blood glucose levels may be toggled between a 3-hour time frame and a 12-hour time frame. In some embodiments, the home screen may include a simplified display of the current EGV, a curve showing the EGV shown 30 minutes ago, and a curve showing the predicted EGV for the next 30 minutes.

[0120] A message may be displayed on the home screen to remind the user about recommended actions the user can take to improve their therapy. In some embodiments, the mobile app may provide guidance to the user based on a combination of glucose data and / or pen cap placement information. In some embodiments, the app-mediated guidance may be approved by a medical professional via a cloud connection before being provided to the user. For example, in some embodiments, blood glucose data after a cap placement event may indicate that the user typically underdoses or typically overdoses on insulin for a particular meal. In some embodiments, the methods and systems provided herein can then adjust user-specific treatment parameters or recommended dosages of rapid-acting insulin based on the blood glucose data after each cap placement event. In some embodiments, glucose data after or before each cap placement event may be transmitted to a medical professional to allow the medical professional to update user-specific dosage parameters or recommended dosages for that user (which may be based on time of day). In some embodiments, data before and after each cap placement event may indicate that the user typically takes rapid-acting insulin after the start of a meal, and may be adapted to prompt the user to take a bolus dose before the meal if the user plans to eat. In some embodiments, the data and blood glucose levels before and after each cap wearing event may be used to recommend injection timing, relative to when to start a meal after an injection. In some embodiments, the data and / or blood glucose levels before and after each cap wearing event may be used to recommend modifications to the dose of insulin taken by the subject. Again, such guidance may be automatic and approved and / or developed by a medical professional.

[0121] In some embodiments, the blood glucose levels may be further used to track and / or make recommendations regarding the type of insulin taken. In some cases, the blood glucose levels may be analyzed in conjunction with dose capture data to determine if the wrong insulin has been taken. In some cases, the blood glucose data may be analyzed in conjunction with temperature sensor data from the pen cap to determine if the insulin is bad, if the wrong insulin has been taken (e.g., as described above), or if there is some other problem with the therapy or associated device.

[0122] The mobile application may be adapted to allow the user to provide additional information that can be used to determine how often the user complies with the recommended dosage. In some embodiments, the user may be provided with the possibility to enter a dose for each cap-on event and / or may enter multiple doses (e.g., amounts of insulin taken over a selected period of time, such as more than one day) into the mobile application or directly into the pen cap. For example, marks along the graph may be tapped by the user to allow the user to enter the doses administered.

[0123] 17 shows another example display 300 of a portion of a system (e.g., of a mobile device such as mobile device 140 shown in FIG. 7). As shown in FIG. 9, display 300 may be somewhat similar to that shown in FIG. 16 and may include a graphical representation of blood glucose data using marks (e.g., circles 302) along the x-axis that indicate the timing of events related to system 10, such as when glucose readings are received from an associated glucose monitor (e.g., a flash monitor). The circles 302 may be connected by (e.g., located above) a trend line 304 of the user's blood glucose levels.

[0124] In embodiments where data is received only intermittently from the blood glucose monitor (e.g., when segments or blocks of data regarding BGV are downloaded at discrete time periods upon request), data prior to the current data point circle 302 indicating the most recent glucose reading (e.g., the area between the current circle 302 and the previous circle 302) may be received from the glucose monitor and added to the trend line 304. In some embodiments, a separate marker (e.g., the most recent circle 306) may be positioned at the most recent reading (e.g., the most recent circle 302) and may be visually distinct from the previous circle 302. In some embodiments, the time of the last scan may be displayed on the display 300. In some embodiments, the horizontal position of the most recent circle, i.e., marker 306, on the trend line 304 may also be indicated on the display 300 using a marker (e.g., a vertical line 308).

[0125] In some embodiments, the pen cap may interrogate the blood glucose sensor when the device is placed near the sensor and / or when a button (e.g., the virtual scan sensor button 310) is selected or pressed (e.g., and held) by the user. In some embodiments, the display 300 may include an indicator (e.g., a meter 312 extending around the user button 310) that displays measurements related to the system. For example, the meter 312 may display the remaining life of the blood glucose sensor (e.g., the estimated time until the sensor will need to be replaced). As shown, the meter 312 may increment (e.g., grow) or decrement (e.g., retract) around the button 310 according to changes in the associated data. For example, the meter 312 may decrement or increment over time (e.g., resulting in either a solid meter 312 or an empty, or hollow, meter 312) as the blood glucose sensor's life approaches zero. In some embodiments, the meter 312 may display other metrics, such as time since the last scan, time until the next recommended scan, percentage of a previously administered dose (e.g., a correction dose) remaining, etc.

[0126] 18, in some embodiments, the display 300 may allow a user to track previous values ​​on the trend line 304. For example, the user may drag the most recent circle or marker 306 (e.g., along with the vertical line 308) back along the trend line to a previous time period. As shown, the display 300 may track the position of the most recent circle 306 and display the time and blood glucose value for the selected time period.

[0127] In some embodiments, the most recent circle 306 (e.g., along with the vertical line 308) may be anchored to the most recent data position on the trend line 304 and may return to the most recent position when the most recent circle 306 is released by the user. For example, the vertical line 308 may be transformed into a "slingshot" that, when released by the user, may return the circle 306 to the most recent reading position.

[0128] In some embodiments, the user may occasionally be asked to estimate the number of units of insulin remaining in the pen. In some embodiments, the user may be asked to take a picture of the insulin pen, and the app may be adapted to analyze the image of the insulin pen to determine the approximate number of units left in the pen. For example, FIG. 19 shows an exemplary user interface through which a user may take a picture of the pen using a smartphone camera. In some embodiments, the user interface may overlay a real-time view of the smartphone camera with guide lines corresponding to features of the pen to assist the user in aligning the pen with the smartphone camera. In some embodiments, the mobile app may be adapted to automatically snap a picture of the pen when features seen by the smartphone camera are aligned with guide lines 150. As shown, guide lines 150 may include lines indicating a window in the pen that allows the plunger to be viewed. In some embodiments, the guide lines may move relative to the position of the pen. In some embodiments, the mobile app may detect if the pen is too close or too far from the camera and prompt the user to move the pen relative to the smartphone camera. In some embodiments, the camera may automatically zoom in on the pen. In some embodiments, the user may be asked to estimate how often the user complies with the recommended dosage. In some embodiments, the device may automatically analyze the amount of insulin when the pen or a portion thereof is in view of the mobile device (e.g., a camera).

[0129] In one embodiment, the device may automatically analyze the insulin vial and infer meal information based on changes in the image of the insulin vial. For example, based on several consecutive images, meal intake and meal frequency may be inferred based on changes in the amount of insulin in the vial and the type of insulin (i.e., fast acting).

[0130] In some embodiments, the pen may include indicators (e.g., graduated markings) that allow a user to easily identify the position of a part of the pen (e.g., the plunger) and enter an associated value into an application.

[0131] The pen cap may be configured to provide insight into dosage recommendations that the user is likely to follow. For example, as described in U.S. Patent Application Publication No. 15 / 717,805, entitled "Medicine Injection And Disease Management Systems, Devices and Methods," filed September 27, 2017, the contents and disclosure of which are incorporated herein by reference in their entirety, the pen cap (regardless of the presence of any dosage capture features incorporated into the pen cap) may include meal notification categories (e.g., S, M, L), and data from each notification may indicate whether the user is likely to have administered the appropriate amount for an S, M, or L meal. In some embodiments, a button on the pen cap 122 may be pressed multiple times to sequentially display recommendations for an S meal, an M meal, and an L meal, and the methods and systems provided herein may assume that the user administered insulin based on the last displayed recommendation. In some embodiments, information added via the mobile application indicating the amount of insulin left in the pen at various intervals (daily, every few days, weekly) can indicate whether the user is generally following treatment recommendations or whether the user is ignoring them. In some embodiments, the methods and systems provided herein can analyze glucose data, pen cap attachment information, data regarding the amount of insulin left in one or more pens, and / or answers to questions posed via the mobile app to identify a likelihood or assessment of the user's compliance with recommended dosages, which may be used by the methods and systems provided herein to determine whether to adjust the recommended dosage or provide guidance to the user.

[0132] System setup The treatment management systems provided herein can be set up using any suitable method. In some embodiments, a medical professional can enter initial treatment parameters through a web portal or directly on the user's mobile device (e.g., during an appointment). In some embodiments, the user may enter initial treatment parameters based on advice from a physician. The treatment management systems provided herein provide a way for users to clearly understand their treatment settings, thereby building user confidence in the system.

[0133] FIG. 20 illustrates an exemplary initial screen for a mobile application of a mobile device 140 for a diabetes management system, such as the system shown in FIG. 1A, FIG. 1B, or FIG. 1C. The initial screen allows a user to click a start button to enter their settings, which may be as directed by a healthcare professional. The user may be given the opportunity to enter information about their insulin therapy (e.g., brand and / or generic names of long-acting and / or rapid-acting insulins, average dosage information, etc.). In some embodiments, the user may be asked to select a brand of long-acting insulin and / or a brand of rapid-acting insulin from a list of known brands. In some cases, the user may also be queried as to whether they will be using two insulin pens or one insulin pen, and product configuration may be performed on-the-fly during setup. For example, some treatment settings may be automatically configured depending on the selected insulin brand. In some embodiments, prescription information may be associated with the pen cap (e.g., downloaded from the treatment management system or entered by a healthcare provider), and the list of insulin brands may be curated based on the prescription information. Furthermore, treatment settings may be automatically configured depending on the prescription information.

[0134] The mobile application may present the screen shown in FIG. 21 , which prompts the user to enter a daily dose of long-acting insulin pen (e.g., in whole units or half units, or other resolution based on the resolution of the user's long-acting insulin pen 110). The user interface may, for example, use a sliding wheel or a numeric keypad as shown. In some embodiments, the user may be prompted to enter the time of day they normally inject long-acting insulin. Another screen, as shown in FIG. 22 , allows the user to enter standard doses for different sized meals. In some embodiments, each of these fields may be pre-populated with a recommended amount based on the user's daily dose of long-acting insulin, and these values ​​may be based on a population model. For example, the pre-populated amounts may be pre-populated based on relationships as described in U.S. Patent Application No. 15 / 717,805, but the user interface allows the user to press within the fields to override these pre-populated numbers and enter their own dose for each meal size. In some embodiments, the mobile application can show the user example meals that fit each category, allowing the user to compare their mental models of what constitutes a small, medium, and large meal with the system's hypotheses. FIG. 23 shows an example user interface for showing example meals with serving sizes that fit into different categories. For example, for "low carb" meals, each meal shown has a similar glycemic impact (e.g., similar carbohydrate content). Similarly, "medium carb" and "high carb" meals also have a similar glycemic impact (e.g., identical carbohydrate content) for the meals shown in each category. For example, meals shown in "low carb" may each contain approximately 15-20 grams of carbohydrates, meals shown in "medium carb" may each contain 35-45 grams of carbohydrates, and meals shown in "high carb" may each contain 60-80 grams of carbohydrates. After setting the meal dosage, the user can then select a glucose target or glucose target range.

[0135] 24 shows an exemplary user interface that allows a user to adjust the glucose target value up or down. In some embodiments, the glucose target value can be set to a default value at a preset number (e.g., 100 mg / dl, 80 mg / dl, 120 mg / dl, etc.).

[0136] The screen shown in FIG. 25 allows the user to review (and, optionally, further adjust) the settings.

[0137] The diabetes management systems provided herein, in some embodiments, can use data about the user to customize one or more corrective dosages.

[0138] In some embodiments, a user interface available on the mobile device 140 or from a remote server via the cloud allows a healthcare professional or PWD to set an ISF or input other data to specify correction doses. In some embodiments, the glucose target values ​​set in FIG. 24 may be used along with an ISF (or increment value) entered by or at the direction of a healthcare professional to generate a linear sliding scale correction chart. For example, a formula that may define a linear sliding scale correction chart is as follows: Correction dose = rounddown (current blood glucose - glucose target) / ISF.

[0139] In some embodiments, the glucose target set in FIG. 24 can define the middle range of the glucose target range, and a formula can calculate the correction dose using the lower limit of the glucose target range. In some embodiments, the ISF can be estimated from the mathematical relationship between the user's daily dose of long-acting insulin. FIG. 26 shows how a sliding scale chart can be determined by the ISF or interval and the glucose goal or target. In some embodiments, a user interface on the mobile application or within the web portal can create a sliding scale chart for the PWD, caregiver, or healthcare professional prior to accepting the summary shown in FIG. 24. In some embodiments, the sliding scale chart can be included in the treatment summary. The sliding scale chart can simplify the user's understanding of how the system adjusts their therapy based on real-time blood glucose readings from the glucose sensor. In some embodiments, the user interface can allow the user to update the increment or start, and dynamically update the generated sliding scale correction chart (e.g., as shown in FIG. 33) to allow the healthcare professional or PWD to match the generated sliding scale correction chart to their desired treatment settings.

[0140] 27-30 illustrate different options that may be presented to a user via a user interface that allows a mobile application to create a sliding scale (e.g., as shown in FIG. 18). As shown in FIG. 27, the mobile application may first prompt a user (e.g., the subject and / or caregiver) to input values ​​(e.g., based on past use) related to actions taken by the subject during blood glucose management, such as historical data related to the amount (e.g., units) of insulin (e.g., rapid-acting insulin) taken in response to a particular blood glucose range. As shown in FIG. 28, two or more ranges may be entered to create a user-input scale, which may (e.g., result in) a non-linear scale.

[0141] As a second option, the mobile application may prompt the user to directly enter a value for the subject's ISF, as shown in Figure 29. For example, the user may enter the average drop in blood glucose level, measured in milligrams per deciliter (mg / dl), caused by each unit of insulin taken by the subject. In some embodiments, the mobile application may allow the user to enter a target blood glucose level.

[0142] In either option, the mobile application may display a confirmation of the scale manually entered by the user (e.g., a non-linear scale) under the first option, or a confirmation of the scale generated using the ISF values ​​entered by the user (e.g., a linear scale) under the second option.

[0143] The methods, devices, and systems provided herein may detect patterns in blood glucose levels and / or infusions that enable the device or system to understand the impact of administration and determine changes in recommended treatment settings to improve glycemic outcomes. In some embodiments, a mobile device may determine the appropriate treatment changes. In some embodiments, a remote server may determine the appropriate treatment settings. In some embodiments, the methods, devices, and systems may automatically incrementally adjust dosages for different meal sizes, as described in U.S. Patent Application No. 15 / 717,805, incorporated herein by reference. In some embodiments, an algorithm may update the ISF or correction dosage based on the detected pattern. In some embodiments, the methods, devices, and systems may determine whether there are any treatment-related change recommendations and then use the information to inform the user about the pattern or may use a trigger, hint, or suggestion to the user (e.g., a message in the mobile application) to inform the user about the pattern. Examples of these are shown in FIG. 31. For example, the message may be as shown in FIG. 31 and / or may be displayed on the mobile device as shown in FIG. 32. As shown in FIG. 32 , the message may include a screen that shows the user how to make the appropriate changes (e.g., in-app training) and / or a button that takes the user to a screen where the changes can actually be made. Pressing this button may take the user to the screen shown in FIG. 33 , which includes multiple sliders for each meal size. In some embodiments, the user may choose to change only one meal size, or may wish to make a board-wide change by changing the bottom slider. In some embodiments, changing the bottom slider may change the ISF value. In some embodiments, settings may be based on time of day (e.g., breakfast time, lunch time, dinner time), and the user may adjust the setting for specifically one of these meal times or all of these meal times.

[0144] Alerts and Warnings In some embodiments, the diabetes management systems, devices, and methods provided herein may provide notifications, warnings, and / or alerts. In some embodiments, the notifications, warnings, and / or alerts may be automatically triggered in one or more parts of the system, such as, for example, the mobile device, the pen cap, and / or one or more separate alert accessories. In some embodiments, the therapy management systems, devices, and methods provided herein may include a smart pen or pen accessory (e.g., an accessory adapted to be secured to the pen, e.g., the pen cap, and / or another accessory that is integral with, or may be applied to, and / or coupled to, the pen) adapted to provide notifications, treatment recommendations, and / or alerts upon user interaction to obtain blood glucose data. In some embodiments, the therapy management systems, devices, and methods provided herein may include both one or more alert accessories and one or more smart pens or pen accessories, each of which may wirelessly receive blood glucose data (e.g., from a continuous glucose monitor). In some embodiments, the therapy management systems, devices, and methods provided herein may include one or more smart pens or pen accessories that communicate with a blood glucose monitoring system (e.g., a continuous glucose monitor) via a first communication technology (e.g., NFC) and one or more alert accessories that communicate with the blood glucose monitoring system (e.g., the same continuous glucose monitor) via a second communication technology (e.g., UHF, BLE). In some embodiments, the communication technology for communicating blood glucose data to the alert accessory has a greater range than the communication technology for communicating blood glucose data to the smart pen or pen accessory. In some embodiments, the therapy management systems, devices, and methods provided herein may include one or more alert accessories that passively receive blood glucose data (e.g., via wireless communication) as long as they are within communication range, and one or more smart pens or pen accessories that are configured to wirelessly receive blood glucose data only when a user takes an action to cause the smart pen or pen accessory to receive the blood glucose data (e.g., press a button, swipe the pen or pen accessory adjacent to a glucose sensor, etc.).In some embodiments, having a smart pen or pen accessory that receives blood glucose data only upon user interaction can reduce the power consumption of the smart pen or pen accessory, thus reducing the burden on the user to charge or replace the battery of the smart pen or pen accessory. In some embodiments, having an alert accessory as provided herein allows the user to decide when and where to receive disruptive alarms, alerts, and notifications, and further may prevent the user from feeling the need to carry the insulin pen between doses.

[0145] The methods, systems, and devices provided herein can include one or more alert accessories, which can take any suitable form. In some embodiments, the alert accessory can include one or more illuminatable icons. In some embodiments, the alert accessory can include a digital display screen. In some embodiments, the alert accessory can include one or more speakers and / or vibration motors. In some embodiments, the alert accessory contemplated herein can be secured to a smartphone (e.g., as a phone case). In some embodiments, the alert accessory contemplated herein can be secured to a keychain. In some embodiments, the alert accessory contemplated herein can be adapted to function as a bedside alarm clock. In some embodiments, the alert accessory contemplated herein can be adapted to function as a bedside alarm clock.

[0146] In some embodiments, the methods, systems, and devices provided herein may provide guidance regarding the appropriate insulin dosage. In some embodiments, the insulin dosage may be administered using an insulin delivery pen or syringe. In some embodiments, the insulin may be a long-acting insulin. In some embodiments, the insulin may be a rapid-acting insulin. In some embodiments, the insulin delivery pen or its accessories (e.g., cap) can detect the amount of insulin delivered (or the amount of insulin ready to be delivered) from the pen. In some embodiments, the insulin pen or its accessories may include a user interface that displays data or recommendations to the user and / or allows the user to input data into the insulin pen or accessories.

[0147] While the exemplary therapy management system below includes an insulin delivery pen with a dose-trapping pen cap, other embodiments are contemplated in which the functionality disclosed herein is incorporated into other accessories of the insulin delivery pen or into the insulin delivery pen itself. Additionally, while the exemplary therapy management system below includes a single alert accessory (e.g., a CGM fob), other embodiments are contemplated in which multiple alert accessories are included, or in which the functionality of the alert accessories is integrated into a smartphone or other web-connected mobile computing device (e.g., using WiFi or cellular communications).

[0148] In some embodiments, one or more parts of the system (e.g., pen, mobile application, alert accessory) may be configured to present one or more of the following warnings or alerts:

[0149] Glucose alerts: Low glucose, high glucose, high probability of future low glucose, high probability of future high glucose, high blood sugar fluctuations

[0150] Timing Alerts: Alerts to check blood glucose (e.g., for specific time intervals during the day), meal timing, pen cap removal for specific periods, and overlapping doses (e.g., removing the pen cap twice within a short period of time)

[0151] Rapid-acting insulin alerts: Correction dose taken, missed rapid-acting dose, unsafe rapid-acting dose, over-threshold dose

[0152] Long-acting insulin alerts: Long-acting dose taken, long-acting dose forgotten, unsafe long-acting dose, dose above threshold

[0153] Insulin Switch Alert: Unsafe dose intake - dose switching, pen cap misuse

[0154] Temperature Alert: As above, detected insulin is out of range

[0155] Maintenance alerts: Out of insulin, low power, sensor failure, sensor expired

[0156] Upgradeable System The diabetes management systems provided herein may be adapted to add or remove components and / or be configured based on the needs of the person with diabetes (PWD). For example, Figures 34A-34D show various systems and associated communication architectures that may be used by PWDs with different types of diabetes (Type 1 or Type 2 as shown, or further including gestational or other types of diabetes), different stages of diabetes, and / or different preferences for diabetes monitoring and / or treatment methods. In some cases, the methods and devices provided herein may be adapted to identify when additional treatment is needed and / or the addition of additional treatments or devices to the treatment and / or system is recommended.

[0157] FIG. 34A shows a system 3410 including only a BGM 150, a mobile device 140 with a mobile app, a long-acting insulin pen 110, and a long-acting pen cap 112. The system 3410 can communicate with a cloud service 250 via the mobile device 140, as described above. The system 3410 may be suitable for use by PWDs who do not require mealtime insulin (e.g., those with early-stage type 2 diabetes and / or gestational diabetes) or who do not wish to track rapid-acting insulin doses. The BGM 150 is a blood glucose meter adapted to determine an estimated glucose value (EGV) by using a test strip to analyze an in vitro blood sample. As shown, the BGM 150 can transmit a single-point EGV to the pen cap 112 via a BLE communication link 3401. The EGV from the BGM 150 can then be transmitted from the pen cap 112 to the mobile application 140 via a BLE communication link 3405 and via the mobile application 140 to the cloud service 250 for analysis via network communication 3409. The BLE communication link 3405 can also transmit pen cap wear data to the mobile application 140, which can also be transmitted via link 3409 to the web service 250. The mobile application 140 can display a graph of the most recent EGV and / or the collected EGV. A recommended dose of long-acting insulin can be displayed on the pen cap 112 in a manner similar to that shown in FIGS. 6 and 35A. The system 3410 can prompt the user to collect a fasting EGV using the BGM 150. The system 3410 can use the fasting EGV to recommend a change to the displayed recommended dose of long-acting insulin or automatically change the recommended dose using standard long-acting insulin titration techniques or any other suitable algorithm. In some cases, an algorithm can be used by the system 3410 to determine whether the PWD should add rapid-acting insulin to their therapy.

[0158] FIG. 34B shows a system 3420 that includes the components of system 3410 but adds a rapid-acting insulin pen 120 and a rapid-acting pen cap 122. System 3420 may be adapted for use by a PWD who requires both long-acting and rapid-acting insulin but who desires to monitor EGV with a BGM instead of a continuous or flash glucose monitor. When a rapid-acting pen cap is added to the system, communication link 3401 is removed and the long-acting pen cap 112 does not receive EGV from the BGM 150. This is because the BGM value is not used to determine an immediate dose of long-acting insulin, but this value may be used to determine a correction dose of rapid-acting insulin. As shown, the BGM 150 can transmit a single-point EGV to the pen cap 122 over BLE communication link 3402. The EGV from the BGM 150 can then be transmitted from the pen cap 122 to the mobile application 140 via BLE communication link 3406 and via the mobile application 140 to the cloud service 250 for analysis via network communication 3409. BLE communication links 3405 and 3406 can also transmit pen cap wear data to the mobile application 140, which may also be transmitted to the web service 250 via link 3409. The mobile application 140 can display a graph of the most recent EGV and / or the collected EGV. Recommended doses of fasting and long-acting insulin can be displayed on the pen cap 112 in a manner similar to that shown in FIGS. 3-6, 35A, and 35B. The system 3420 can prompt a user to collect fasting and / or postprandial EGV using the BGM 150. For example, the system 3420 may optionally trigger a reminder to the user to check their EGV at a predetermined time after the pen capping event to collect a post-meal EGV.The system 3420 can use the fasting EGV to recommend a change in the displayed recommended dose of long-acting insulin, or can automatically change the recommended dose using standard long-acting insulin titration techniques or any other suitable algorithm. The system 3420 can use the postprandial EGV to recommend a change in the displayed recommended dose of rapid-acting insulin, or can automatically change the recommended dose using standard insulin titration techniques or any other suitable algorithm. In some cases, using algorithms in the system 3420, the PWD can determine whether a continuous glucose monitor should be added to help the PWD achieve better glycemic control.

[0159] FIG. 34C illustrates a system 3430 that includes the components of system 3420 but adds a continuous glucose monitor 130. The CGM 130 allows both broadcasting of data via BLE or UHF radio and user-initiated data transfer via NFC communication, and either or both communication methods may be used to send the EGV from the CGM 130 to the pen cap 122 and / or mobile application 140. Because long-acting insulin delivery does not use a correction component, direct communication between the CGM 130 and the pen cap 112 is not required. For example, the NFC communication link 3403 may enable the pen cap 122 to receive the EGV from the CGM 130 once the user decides to obtain an EGV, such as by using the method shown in FIG. 2 and described above. The BLE communication link 3402 still permits transfer of the EGV from the BGM 150 to the pen cap 122. The EGVs from the BGM 150 and / or CGM 130 can then be transmitted from the pen cap 122 to the mobile application 140 via BLE communication link 3406 and via the mobile application 140 to the cloud service 250 for analysis via network communication 3409. Additionally, the EGVs from the CGM 130 may be received by the mobile application 140 via communication link 3404, which may include both BLE and NFC communication. BLE EGV broadcasts may be used to trigger EGV-based warnings or alerts notified by the mobile application 140. Missing EGVs may be filled by scanning the CGM 130, mobile application 140, or pen cap 122 to obtain data from multiple hours (e.g., 4 hours, 6 hours, 8 hours, or 10 hours) prior to the EGV. BLE communication links 3405 and 3406 can also transmit pen cap attachment data to the mobile application 140, which may also be transmitted to the web service 250 via link 3409. The recommended dosages of fast-acting and long-acting insulin may be displayed on the pen cap 112 in a manner similar to that shown in Figures 3-6, 35A, and 35B.The system 3430 can use the EGV in combination with dosage data (e.g., timing data) to recommend a change in the displayed recommended dose of rapid-acting insulin, or can automatically change the recommended dose using standard insulin titration techniques or any other suitable algorithm.

[0160] 34C also shows that system 3440 may include the same components. System 3440 differs from system 3430 in that it includes pen caps 112 and 122 adapted to detect the amount of insulin remaining in insulin pens 110 and 120, which may be used to determine an insulin dose. Other methods for detecting the dose in a cap or other accessory, or as part of a smart pen or smart inhaler, may be used and are therefore contemplated herein. Additionally, system 3440 may use the captured dosage data to make more proactive automatic changes to user-specific dosage parameters.

[0161] 34D illustrates the continuum of care and how components may be added to each system 3410-3440 to upgrade the system. Additionally, system 3450 is an automated insulin delivery system using an insulin pump. In some cases, systems 3440 or 3430 may be used to detect candidates for switching to pump therapy, such as system 3450. In some cases, system 3450 may include pen caps 112 and / or 122, which may allow a user to selectively move between injection therapy (e.g., MDI therapy) and pump therapy (e.g., infusion pump therapy).

[0162] FIG. 35A shows exemplary displays 114A-114C of pen cap 112. FIG. 25B shows exemplary displays 124A-124E of pen cap 122. In pen cap 112, display 114A may be a standard display when the pen cap is not in use. As described above, display 114 may be a bi-stable display capable of retaining an image without excessive power supply. Display 114A may include an insulin type label, so a user can immediately know the insulin type by looking at pen cap 112. When a button is pressed or cap 112 is removed, the time of the last dose may be displayed on display 114B. In some cases, if the time since the last dose is less than a threshold (e.g., less than 12 hours), a warning may be displayed and / or the pen cap may refuse to provide a recommended dose. Display screen 114C shows the recommended dose.

[0163] In the pen cap 122, display 124A may be a standard display when the pen cap is not in use. As noted above, display 124 may be a bi-stable display capable of retaining an image without requiring excessive power. Display 124A may include an insulin type label, so the user can immediately see the insulin type by looking at the pen cap 122. When a button is pressed or cap 122 is removed, the time of the last dose may be displayed on display 124B. Once an EGV is acquired (e.g., via scanning the CGM 130), display 124C may be displayed. As shown, display 124C includes a correction dose, which may be based on the EGV (and optionally trend data) using any suitable technique. In some cases, the correction dose may only be displayed if the time since the last dose exceeds a predetermined number of hours and the pen cap 122 is still on the pen 120. In some cases, if the time since the last dose is less than a threshold (e.g., less than 1 hour, less than 30 minutes), a warning may be displayed and / or the pen cap may refuse to provide a recommended dose. Display screen 124D shows a meal dose recommendation. Display screen 124E shows a meal + correction dose. In some cases, display 124 can be cycled through display screens 124C-124E by successive button presses.

[0164] The embodiments described herein may involve the use of special purpose or general purpose computers, including various computer hardware or software modules, as discussed in more detail below.

[0165] The embodiments described herein may be implemented using computer-readable media for carrying or having computer-executable instructions or stored data structures. Such computer-readable media may be any available media that can be accessed by a general-purpose computer or a special-purpose computer. A special-purpose computer is intended to be broadly interpreted to encompass embedded systems, microcontrollers, application-specific integrated circuits, digital signal processors, and general-purpose computers programmed for specific purposes. A segment (e.g., a code segment or a data segment) may refer to a portion (e.g., an address) of memory, virtual memory, or an object file.

[0166] By way of example, and not limitation, such computer-readable media include random access memory (RAM), read-only memory (ROM), electrically erasable programmable read-only memory (EEPROM), read-only compact disc read-only memory (CD-ROM) or other optical disk storage, magnetic disk storage or other magnetic storage, flash memory devices (e.g., solid-state memory devices), or any other storage medium that can be used to hold or store desired program code in the form of computer-executable instructions or data structures and that can be accessed by a general-purpose or special-purpose computer. Combinations of the above may be included within the scope of computer-readable media.

[0167] Computer-executable instructions include, for example, instructions and data that cause a general-purpose computer, special-purpose computer, or special-purpose processing device (e.g., one or more processors) to perform a particular function or set of functions. Although the subject matter has been described in language specific to structural features and / or methodological acts, it should be understood that the subject matter defined in the appended claims is not necessarily limited to such specific features or acts. Rather, the specific features and acts are disclosed as exemplary forms of implementing the claims.

[0168] Any ranges expressed herein (including the claims) are intended to have the broadest possible interpretation. For example, unless explicitly stated, ranges include their endpoints (e.g., a range "between X and Y" includes X and Y). In addition, ranges described using the terms "approximately" or "about" should be understood to have the broadest meaning consistent with the understanding of one of ordinary skill in the art. Additionally, the terms "approximately" or "substantially" include anything within 10% or 5%, or within manufacturing or typical tolerances.

[0169] The features of the various embodiments described herein are not mutually exclusive and can exist in various combinations or permutations even if such combinations or permutations are not expressly set forth herein without departing from the scope of the present disclosure. Indeed, variations, modifications, and other implementations of what is described herein will occur to those skilled in the art without departing from the scope of the present disclosure. Accordingly, the present invention should be defined not solely by the foregoing illustrative description, but solely by the following claims and their legal equivalents.

[0170] Further non-limiting embodiments of the present disclosure relate generally to caps for insulin injection pens and related methods and systems.

[0171] Embodiment 1: A pen cap for a manual insulin delivery device, comprising: a wireless communication interface configured to receive blood glucose data from a glucose sensor system; at least one detection circuit configured to detect one or more cappings and one or more uncappings of the pen cap from the manual insulin delivery device; at least one user interface configured to present one or more of therapy-related information, therapy recommendations, and timing information associated with the detected cappings or the detected uncappings of the pen cap; and a processor and a memory, wherein the memory comprises: a data segment configured to store one or more of at least one user-specific dosage parameter and a recommended dosage; and a code segment configured to store instructions, when executed by the processor, adapted to enable the processor to identify content presentable by the at least one user interface in response to the detected cappings or the detected uncappings of the pen cap.

[0172] Embodiment 2: A pen cap as described in embodiment 1, wherein the user interface is configured to present a recommended correction dose of insulin in response to determining that the replacement cap has been attached to the manual insulin delivery device for at least a threshold period of time, the recommended correction dose of insulin being based on an insulin sensitivity factor and a target glucose value stored in a data segment of the memory.

[0173] Embodiment 3: A pen cap described in any one of embodiments 1 to 2, wherein the wireless communication interface is configured to communicate with the glucose sensor system via a short-range wireless communication protocol when in proximity to at least a portion of the glucose sensor system.

[0174] Embodiment 4: A pen cap according to any one of embodiments 1 to 3, wherein the wireless communication interface is configured to transmit messages related to insulin therapy.

[0175] Embodiment 5: The pen cap of any one of embodiments 1 to 4, wherein the message comprises an indicator, and the indicator is related to insulin therapy.

[0176] Embodiment 6: A pen cap as described in any one of embodiments 1 to 5, wherein the message is configured to be received by one or more insulin therapy applications executing on one or more mobile computing devices.

[0177] Embodiment 7: The pen cap according to any one of embodiments 1 to 6, wherein the wireless communication interface is configured to transmit the message by broadcasting the advertising message.

[0178] Embodiment 8: A pen cap according to any one of embodiments 1 to 7, wherein the wireless communication interface is configured to transmit messages using data transmission.

[0179] Embodiment 9: A pen cap as described in any one of embodiments 1 to 8, wherein the wireless communication interface is configured to automatically transmit data to an insulin therapy application running on a mobile device.

[0180] Embodiment 10: A pen cap according to any one of embodiments 1 to 9, wherein the wireless communication interface is configured to automatically communicate with a mobile application.

[0181] Embodiment 11: A pen cap described in any one of embodiments 1 to 10, wherein the wireless communication interface is adapted to communicate with the glucose sensor system using a first wireless communication technology having a first communication range, and the wireless communication interface is adapted to communicate with the mobile computing device using a second wireless communication technology having a second communication range, and the second communication range is greater than the first communication range.

[0182] Embodiment 12: A pen cap according to any one of embodiments 1 to 11, wherein the glucose sensor system comprises a flash glucose monitor.

[0183] Embodiment 13: A pen cap described in any one of embodiments 1 to 12, wherein the content includes a presentation of the percentage of active insulin remaining in the user based on the time of previous capping and cap removal of the replacement pen cap and the current time.

[0184] Embodiment 14: A pen cap described in any one of embodiments 1 to 13, wherein the code segment is configured to store instructions adapted, when executed by the processor, to enable the processor to determine the amount of insulin remaining in the manual insulin delivery device and to determine the dose at the previous cap-on or cap-off time, and at least one user interface is configured to display an estimate of the active insulin remaining in the user in response to the current time and one or more administration events.

[0185] Embodiment 15: A pen cap as described in any one of embodiments 1 to 14, wherein the memory segment is configured to store administration events over a first period of time, the period including a first block of distinct time units, a start time unit of the distinct time units of the first block, and an end time of the first block of distinct time units, the end time corresponding to a current time, and at least one of the distinct time units being associated with one of the administration events.

[0186] Embodiment 16: A pen cap described in any one of embodiments 1 to 15, wherein the code segment is configured to store instructions adapted, when executed by the processor, to enable the processor to record a dosing event in response to a detected cap attachment and / or a detected cap removal, and to associate the dosing event with one or more of the distinct time units.

[0187] Embodiment 17: A pen cap described in any one of embodiments 1 to 16, wherein the code segment is configured to store instructions that, when executed by the processor, cause the processor to select a block of discrete time units forming a first period in response to an active insulin estimation request and a current time, select one or more administration events associated with the first period, and determine an estimate of active insulin remaining in the user in response to the current time and the one or more administration events.

[0188] Embodiment 18: A pen cap described in any one of embodiments 1 to 17, wherein at least one user interface is configured to display an estimate of remaining active insulin as a percentage of the dose associated with the most recent administration action.

[0189] Embodiment 19: The pen cap of any one of embodiments 1 to 18, further comprising an inner sleeve and an outer housing, wherein the inner sleeve and the outer housing define a watertight cavity.

[0190] Embodiment 20: A pen cap described in any one of embodiments 1 to 19, wherein at least a portion of one or more of at least one detection circuit, processor, memory, and wireless communication interface is held within a watertight cavity.

[0191] Embodiment 21: A pen cap according to any one of embodiments 1 to 20, further comprising an adapter configured to reversibly couple with a corresponding adapter in a manual insulin delivery device.

[0192] Embodiment 22: An insulin delivery system comprising: an insulin injection pen for delivering insulin; and a pen cap adapted to be reversibly secured to the insulin injection pen, the pen cap comprising: a wireless communication interface adapted to receive blood glucose data from a glucose sensor system; at least one circuit adapted to detect whether the pen cap is secured to the insulin injection pen; at least one user interface that communicates treatment-related information, treatment recommendations, or previous capping or uncapping times of the pen cap from the insulin injection pen; a memory that stores at least one user-specific dosage parameter or recommended dosage; and at least one processor adapted to determine content to be presented by the user interface, wherein the at least one processor determines the content using information about one or more cappings or uncappings.

[0193] Embodiment 23: An insulin delivery system as described in embodiment 22, wherein the user interface is adapted to display a recommended correction dose of insulin based on the insulin sensitivity factor and the target glucose value stored in the memory when the pen cap has been attached to the insulin injection pen for at least a threshold period of time.

[0194] Embodiment 24: An insulin delivery system described in any one of embodiments 1 to 23, wherein the content includes a presentation of the percentage of active insulin remaining in the user based on the time of previous capping and uncapping of the pen cap and the current time.

[0195] Embodiment 25: An insulin delivery system described in any one of embodiments 1 to 24, wherein the replacement pen cap is adapted to identify the amount of insulin remaining in the insulin injection pen and to identify the dose at the time of the previous capping or cap removal, and the pen cap displays an estimate of the active insulin remaining in the user based on the current time, as well as the time and dose associated with one or more previous cappings or cap removals of the pen cap.

[0196] Embodiment 26: A diabetes management system comprising: a mobile computing device configured to receive one or more user-specific dosage parameters or predetermined dosage amounts from a user; a glucose sensor system configured to collect and wirelessly transmit blood glucose data; and a pen cap adapted to be reversibly secured to an insulin injection pen, the pen cap comprising: a wireless communication interface adapted to receive blood glucose data from the glucose sensor system and the one or more user-specific dosage parameters or predetermined dosage amounts from the mobile computing device; at least one circuit adapted to detect whether the pen cap is secured to the insulin injection pen; at least one user interface that communicates treatment-related information, treatment recommendations, or a previous capping or de-capping time of the pen cap from the insulin injection pen; a memory that stores at least one user-specific dosage parameter or recommended dosage amount received from the mobile computing system; and at least one processor adapted to determine content to be presented by the user interface, wherein the at least one processor determines the content using information about one or more cappings or de-cappings.

[0197] Embodiment 27: The diabetes management system of embodiment 26, further comprising an insulin injection pen adapted to be reversibly secured to the pen cap.

[0198] Embodiment 28: A diabetes management system described in any one of embodiments 1 to 27, wherein the user interface is adapted to display a recommended correction dose of insulin based on the insulin sensitivity factor and the target glucose value stored in the memory when the replacement pen cap has been attached to the insulin injection pen for at least a threshold period.

[0199] Embodiment 29: The diabetes management system of any one of embodiments 1 to 28, further comprising a long-acting insulin pen, a rapid-acting insulin pen, and at least two pen caps, wherein at least two of the pen caps include a first pen cap adapted to be secured to the long-acting insulin pen and a second pen cap adapted to be secured to the rapid-acting insulin pen.

[0200] Embodiment 30: A diabetes management system described in any one of embodiments 1 to 29, wherein the wireless communication interface is configured to communicate with the glucose sensor system via a short-range wireless communication protocol when the pen cap is in proximity to at least a portion of the glucose sensor system.

[0201] Embodiment 31: A diabetes management system described in any one of embodiments 1 to 30, wherein the wireless communication interface is adapted to communicate with the glucose sensor system using a first wireless communication technology having a first communication range, and the wireless communication interface is adapted to communicate with the mobile computing device using a second wireless communication technology having a second communication range, and the second communication range is greater than the first communication range.

[0202] Embodiment 32: A diabetes management system according to any one of embodiments 1 to 31, wherein the glucose sensor system comprises a flash glucose monitor.

[0203] Embodiment 33: A smart electronics module that can be integrated with a manual insulin delivery device, comprising: a wireless communication interface configured to receive blood glucose data from a glucose sensor system; at least one detection circuit configured to detect one or more cappings and one or more uncappings of a pen cap from the manual insulin delivery device; at least one user interface configured to present one or more of therapy-related information, therapy recommendations, and timing information associated with the detected cappings or detected uncappings of the pen cap; a processor and a memory, wherein the memory comprises a data segment configured to store one or more of at least one user-specific dosage parameter and a recommended dosage; and a code segment adapted, when executed by the processor, to enable the processor to identify content presentable by the at least one user interface in response to the detected cappings or the detected uncappings of the pen cap.

[0204] Embodiment 33: A system, method, or device described in any one of embodiments 1 to 32, wherein the blood glucose data is an interstitial fluid glucose concentration or is based on an interstitial fluid glucose concentration.

[0205] Embodiment 34: A system, method, or device described in any one of embodiments 1 to 33, wherein the blood glucose data is a blood glucose value correlated to interstitial fluid glucose concentration.

[0206] Embodiment 35: A system, method, or device described in any one of embodiments 1 to 34, wherein the blood glucose data is a blood glucose level.

[0207] Additional non-limiting embodiments of the present disclosure relate generally to therapy management systems, methods, and devices.

[0208] Embodiment 1: A reusable accessory for a manual medication delivery device, the reusable accessory comprising: a wireless communication interface configured to receive analyte measurement data from an analyte sensor system; a detection circuit configured to detect administration events associated with administration operations in the manual medication delivery device and to store a record for each one or more administration events, the record including an administration time of the administration event; a recommendation system configured to provide one or more medication dosage recommendations in response to one or more of the analyte measurement data and the administration event; and an adapter configured to reversibly couple to a predetermined portion of the manual medication delivery device.

[0209] Embodiment 2: The reusable accessory of claim 1, wherein the manual medication delivery device is a medication injection pen, the reusable accessory is a reusable pen cap for the medication injection pen, the administration event associated with the one or more administration operations is one or more of a cap-on event or a cap-removal event, and the detection circuit is configured to detect the cap-on event or the cap-removal event in response to the sensor signal.

[0210] Embodiment 3: A reusable accessory according to any one of embodiments 1 to 2, further comprising a timer configured to count the number of time units from a cap removal event to a subsequent cap installation event, wherein the circuitry is configured to record the administration time in response to a particular count exceeding a threshold number of time units.

[0211] Embodiment 4: A reusable accessory described in any one of embodiments 1 to 3, wherein the wireless communication interface is configured to receive analyte measurement data via a first wireless connection when the wireless communication interface is positioned in proximity to at least a portion of the analyte sensor system.

[0212] Embodiment 5: A reusable accessory described in any one of embodiments 1 to 4, wherein the wireless communication interface is configured to communicate administration events, treatment parameters, and analyte measurement data with a mobile computing device via a second wireless connection.

[0213] Embodiment 6: A reusable accessory described in any one of embodiments 1 to 5, wherein the wireless communication interface is configured to receive treatment parameters from a mobile computing device.

[0214] Embodiment 7: A reusable accessory described in any one of embodiments 1 to 6, wherein the first wireless connection has a first communication range, the second wireless connection has a second communication range, and the second communication range is greater than the first communication range.

[0215] Embodiment 8: A reusable accessory according to any one of embodiments 1 to 7, wherein the wireless communication interface includes an NFC chip and the first wireless connection consists of an NFC communication between the reusable accessory and the analyte sensor system.

[0216] Embodiment 9: A reusable accessory described in any one of embodiments 1 to 8, wherein the wireless communication interface comprises a radio adapted to enable Bluetooth Low Energy communication between the reusable accessory and one or more mobile computing devices.

[0217] Embodiment 10: A reusable accessory according to any one of embodiments 1 to 9, wherein the analyte detection system comprises a blood glucose meter adapted to provide blood glucose data.

[0218] Embodiment 11: A reusable accessory described in any one of embodiments 1 to 10, wherein the analyte sensor system is a flash glucose monitor adapted to provide glucose data via near-field wireless communication.

[0219] Embodiment 12: A reusable accessory described in any one of embodiments 1 to 11, wherein the analyte sensor system is a continuous glucose monitor adapted to provide blood data via wireless communication (e.g., Bluetooth Low Energy) and optionally near field communication (NFC).

[0220] Embodiment 13: A reusable accessory described in any one of embodiments 1 to 12, further comprising at least one button for enabling and disabling operational modes of the reusable accessory, such as triggering receipt of analyte measurement data, changing the display, stopping or snoozing an alarm, or a combination thereof.

[0221] Embodiment 14: A diabetes management system comprising: a glucose sensor system adapted to wirelessly transmit blood glucose data; an insulin dosage monitoring device adapted to be reversibly connectable to an insulin delivery device, the insulin dosage monitoring device comprising a display, a memory, and a processor, wherein the memory stores insulin therapy dosage parameters, the insulin dosage monitoring device is adapted to detect delivery of insulin from the insulin delivery device, the insulin dosage monitoring device is adapted to wirelessly receive blood glucose data from the glucose sensor system, and the processor is adapted to provide an insulin dosage recommendation based on the stored insulin therapy dosage parameters, the blood glucose data, or a combination thereof; and a mobile computing device including the processor, the mobile computing device configured to intermittently connect to and receive at least one characteristic associated with the insulin monitoring device, the blood glucose data, or a combination thereof via wireless communication.

[0222] Embodiment 15: The system of embodiment 14, wherein the insulin dosage monitoring device comprises a pen cap, and the insulin delivery device is an insulin injection pen, and the pen cap is adapted to detect delivery of insulin from the insulin injection pen by detecting a capping event of the pen cap, which may be inferred to be a dosing event.

[0223] Embodiment 16: A system described in any one of embodiments 1 to 15, wherein the insulin dosage monitoring device comprises a pen cap and the insulin delivery device is an insulin injection pen, and the pen cap is adapted to detect the amount of insulin remaining in the insulin injection pen after each administration to determine the timing and, optionally, the dosage.

[0224] Embodiment 17: A system described in any one of embodiments 1 to 16, wherein the insulin dosage monitoring device comprises an accessory capable of detecting the movement of a plunger or related mechanical element that moves during the injection of insulin from an insulin injection pen.

[0225] Embodiment 18: The system of any one of embodiments 1 to 17, wherein the mobile computing device is configured to receive data regarding at least one characteristic over a selected period of time, including from a past data value to a substantially current value.

[0226] Embodiment 19: A method of managing drug therapy with a manual drug delivery device, the method comprising: receiving analyte measurement data from an analyte sensor system; detecting administration operation events in an accessory configured to be reversibly attached to the manual drug delivery device; storing a record for each of the one or more administration operation events, the record including the administration time of the administration operation; and providing one or more drug dosage recommendations in response to the analyte measurement data.

[0227] Embodiment 20: The method of embodiment 19, further comprising receiving analyte measurement data via the first wireless connection in response to a wireless communication interface positioned proximate to at least a portion of the analyte sensor system.

[0228] Embodiment 21: The method of any one of embodiments 1 to 20, further comprising communicating administration events, treatment parameters, and analyte measurement data to a mobile computing device via a second wireless connection.

[0229] Embodiment 22: The method of any one of embodiments 1 to 21, further comprising receiving treatment parameters from a mobile computing device via a second wireless connection.

[0230] Embodiment 23: A method as described in any one of embodiments 1 to 22, wherein the manual medication delivery device is a medication injection pen, the reusable accessory is a reusable pen cap for the medication injection pen, the administration operation event associated with the one or more administration operations is one or more of a cap on event and a cap removal event, and the detection circuit is configured to detect the cap on event and the cap removal event in response to a sensor signal.

[0231] Embodiment 24: A smart electronics module that can be integrated with a manual medication delivery device, comprising: a wireless communication interface configured to receive analyte measurement data from an analyte sensor system; detection circuitry configured to detect administration operation events and, for one or more administration operations, store a record including the administration time of the administration operation and receive the analyte measurement data received from the analyte sensor system; a recommendation system configured to provide one or more medication dosage recommendations in response to the analyte measurement data; and an adapter configured to reversibly couple to a predetermined portion of the manual medication delivery device.

[0232] Embodiment 25: A system, method, or device described in any one of embodiments 1 to 24, wherein the blood glucose data and / or glucose data is or is based on interstitial fluid glucose concentration.

[0233] Embodiment 26: A system, method, or device described in any one of embodiments 1 to 25, wherein the blood glucose data and / or glucose data is a blood glucose level correlated to interstitial fluid glucose concentration.

[0234] Embodiment 27: A system, method, or device described in any one of embodiments 1 to 26, wherein the blood glucose data and / or glucose data is a blood glucose level.

[0235] Further non-limiting embodiments of the present disclosure generally relate to a user interface for a diabetes management system that includes a flash glucose monitor.

[0236] Embodiment 1: A diabetes management system comprising: a flash glucose monitor adapted to be secured to a person with diabetes (PWD), the flash glucose monitor comprising: a sensing portion adapted to detect blood glucose data at regular time intervals, the regular time intervals being no more than every 15 minutes; and a wireless communication interface adapted to transmit blood glucose data when the wireless communication interface is activated by a user, the blood glucose data transmitted in each wireless communication transmission comprising blood glucose data collected over a data transmission window of at least one hour; and a user interface device, the UI wireless communication interface adapted to receive the blood glucose data transmitted at irregular intervals managed at least in part by user action. a display with a touch screen; a processor and memory adapted to execute instructions in the memory to display a glucose presentation including a graphical display having time of day along the bottom of the graphical display and a curve of glucose values ​​for each received time, the current time being presented on the graphical display to indicate whether a gap exists between the most recent glucose value and the current time, and a single number adjacent to the graphical display representing a single blood glucose measurement, the single number being the most recent glucose value when the user is not touching the screen, and the processor and memory configured to change the single number to a previous glucose value when the user touches a portion of the graphical display corresponding to a previous time.

[0237] Embodiment 2: A diabetes management system as described in embodiment 1, wherein the graphical display includes point indicators positioned along the time axis corresponding to times at which a single numeric value is detected.

[0238] Embodiment 3: A diabetes management system described in any one of embodiments 1-2, wherein the display is configured to allow the user to change the position of the point indicator by pressing a portion of the screen that corresponds to a position along the time axis at a time before the most recent glucose value.

[0239] Embodiment 4: A diabetes management system according to any one of embodiments 1 to 3, wherein the portion of the screen corresponding to the position along the time axis is a portion of the screen showing the time axis.

[0240] Embodiment 5: A diabetes management system according to any one of embodiments 1 to 4, wherein the portion of the screen corresponding to the position along the time axis is a portion of the screen showing a curve of glucose values.

[0241] Embodiment 6: A diabetes management system according to any one of embodiments 1 to 5, wherein the point indicator needs to be pressed and slid along the graphical display to move the point indicator.

[0242] Embodiment 7: A diabetes management system according to any one of embodiments 1 to 6, wherein the point indicator moves back along the glucose value curve after the user stops pressing on the portion of the graphical display.

[0243] Embodiment 8: A diabetes management system according to any one of embodiments 1 to 7, wherein the display further shows a trend arrow adjacent to the single number indicating the rate of change of the glucose value at the time of the single number.

[0244] Embodiment 9: A diabetes management system as described in any one of embodiments 1 to 8, further comprising a reusable accessory adapted to be reversibly secured to the insulin injection pen, the reusable accessory comprising an accessory wireless communication interface adapted to be used by a user to interrogate the flash glucose monitor and receive blood glucose data.

[0245] Embodiment 10: A diabetes management system according to any one of embodiments 1 to 9, wherein the accessory wireless communication interface is adapted to automatically transmit blood glucose data to the user interface device.

[0246] Embodiment 11: A diabetes management system described in any one of embodiments 1 to 10, wherein the reusable accessory is adapted to detect events related to the administration of insulin from an insulin injection pen.

[0247] Embodiment 12: A diabetes management system according to any one of embodiments 1 to 11, further comprising displaying an infusion indicator along the timeline of the graphical display for each detected event.

[0248] Embodiment 13: The diabetes management system of any one of embodiments 1 to 12, wherein the infusion indicator displays the amount of insulin administered.

[0249] Embodiment 14: A diabetes management system according to any one of embodiments 1 to 13, wherein the infusion indicator indicates the type of insulin administered.

[0250] Embodiment 15: A diabetes management system as described in any one of embodiments 1 to 14, further comprising a second reusable accessory adapted to be reversibly secured to a second insulin injection pen, the second insulin injection pen holding a second type of insulin, and the graphical display including different infusion indicators along the time axis for each reusable accessory.

[0251] Embodiment 16: A diabetes management system described in any one of embodiments 1 to 15, wherein the reusable accessory is a replacement pen cap and the event associated with administering insulin from the insulin injection pen is capping the replacement pen cap or removing the cap from the insulin injection pen.

[0252] Embodiment 17: A diabetes management system described in any one of embodiments 1 to 16, wherein the reusable accessory includes an accessory display, and the accessory display shows the most recent glucose value received from the flash glucose monitor.

[0253] Embodiment 18: A diabetes management system described in any one of embodiments 1 to 17, wherein the user interface device is adapted to receive insulin treatment settings and wirelessly communicate the insulin treatment settings to the reusable accessory, and the accessory display is adapted to provide a recommended insulin dosage based on the received insulin treatment settings and the most recent glucose value.

[0254] Embodiment 19: A diabetes management system as described in any one of embodiments 1 to 18, further comprising a blood glucose meter in wireless communication with one or more components of the system, and wherein the graphical display also includes a background music indicator representing the blood glucose measurement value from the blood glucose meter.

[0255] Embodiment 20: A diabetes management system according to any one of embodiments 1 to 19, wherein the single number representing the single blood glucose measurement is adapted to represent a blood glucose measurement or blood glucose value from a blood glucose meter, or a glucose value from a flash glucose monitor.

[0256] Embodiment 21: A system, method, or device described in any one of embodiments 1 to 20, wherein the blood glucose data and / or glucose values ​​are interstitial fluid glucose concentrations or are based on interstitial fluid glucose concentrations.

[0257] Embodiment 22: A system, method, or device described in any one of embodiments 1 to 21, wherein the blood glucose data and / or glucose values ​​are blood glucose values ​​correlated to interstitial fluid glucose concentrations.

[0258] Embodiment 23: A system, method, or device described in any one of embodiments 1 to 22, wherein the blood glucose data and / or glucose value is a blood glucose value.

[0259] Additional non-limiting embodiments of the present disclosure generally relate to devices, systems, and methods for estimating active agent from an injection.

[0260] Embodiment 1: A reusable accessory for a medication injection pen, the reusable accessory adapted to be reversibly attached to the medication injection pen, the reusable accessory configured to detect an event associated with an injection of a medication from the medication injection pen and identify a percentage of the medication that remains active for the injection of the medication based on a current time and a time of the event associated with the injection.

[0261] Embodiment 2: The reusable accessory of embodiment 1, wherein the reusable accessory is a replacement pen cap adapted to be secured to a medication injection pen such that when the replacement pen cap is secured to the medication injection pen, medication cannot be injected into the user, and the event related to medication injection is a capping event or a cap removal event detected in response to capping or capping of the replacement pen cap on the medication injection pen.

[0262] Embodiment 3: A reusable accessory according to embodiment 1 or embodiment 2, wherein the reusable accessory comprises a display, the display providing a visual indication of the amount of active agent remaining as a percentage.

[0263] Embodiment 4: A reusable accessory described in any one of embodiments 1 to 3, wherein the reusable accessory is adapted to identify a dosage for each detected event related to the infusion of the medication, and the reusable accessory identifies an amount of the medication that remains active for the multiple infusions of the medication based on the current time and the time of each of the multiple infusions.

[0264] Embodiment 5: A reusable accessory described in any one of embodiments 1 to 3, wherein the reusable accessory does not detect or identify a dosage for each detected event related to the infusion of a medication.

[0265] Embodiment 6: A reusable accessory according to any one of embodiments 1 to 5, wherein the medication injection pen is an insulin injection pen.

[0266] Embodiment 7: A reusable accessory described in any one of embodiments 1 to 6, wherein the reusable accessory comprises a processor and a memory, the memory storing one or more user-specific dosage parameters, and the processor is adapted to identify a recommended dosage of the drug based at least in part on the user-specific dosage parameters and a calculated value of the active drug for one or more previous injections of the drug.

[0267] Embodiment 8: A reusable accessory according to any one of embodiments 1 to 7, wherein the reusable accessory comprises a wireless communication interface adapted to transmit or receive wireless communications.

[0268] Embodiment 9: A reusable accessory described in any one of embodiments 1 to 8, wherein the reusable accessory is adapted to receive analyte measurement data from the analyte sensor system via a wireless communication interface, and the reusable accessory is adapted to identify a recommended dosage of a medication based at least in part on the received analyte measurement data.

[0269] Embodiment 10: A reusable accessory described in any one of embodiments 1 to 9, wherein the reusable accessory is adapted to transmit data regarding events associated with each injection of the medication to a mobile computing device via wireless communication.

[0270] Embodiment 11: A reusable accessory described in any one of embodiments 1 to 10, wherein the reusable accessory is adapted to receive user-specific dosage parameters from a mobile computing device via wireless communication.

[0271] Embodiment 12: A reusable accessory described in any one of embodiments 1 to 11, wherein the wireless communication interface is configured to receive analyte measurement data from the analyte sensor system.

[0272] Embodiment 13: A reusable accessory described in any one of embodiments 1 to 12, wherein the reusable accessory comprises a recommendation system configured to provide one or more drug dosage recommendations in response to analyte measurement data.

[0273] Embodiment 14: A reusable accessory described in any one of embodiments 1 to 13, wherein the wireless communication interface comprises a first wireless connection having a first communication range and a second wireless connection having a second communication range, the first wireless connection being between the reusable accessory and the analyte sensor system, and the second wireless connection being between the reusable accessory and a mobile application on a remote computing device, and the second communication range being greater than the first communication range.

[0274] Embodiment 15: A reusable accessory described in any one of embodiments 1 to 14, wherein the wireless communication interface includes an NFC chip and the first wireless connection consists of an NFC communication between the reusable accessory and the analyte sensor system.

[0275] Embodiment 16: A reusable accessory described in any one of embodiments 1 to 15, wherein the wireless communication interface comprises a wireless communicator adapted to enable Bluetooth Low Energy communication between the reusable accessory and one or more mobile computing devices.

[0276] Embodiment 17: A reusable accessory described in any one of embodiments 1 to 16, wherein the analyte sensor system is a flash glucose monitor adapted to provide glucose data via near-field wireless communication.

[0277] Embodiment 18: A diabetes care management system comprising: a mobile computing device adapted to receive one or more user-specific dosage parameters or predetermined dosage amounts from a user; a glucose sensor system adapted to collect and wirelessly transmit blood glucose data; and a reusable accessory adapted to be reversibly attached to an insulin injection pen, the reusable accessory comprising: a wireless communication interface adapted to receive the blood glucose data from the glucose sensor system and the one or more user-specific dosage parameters or predetermined dosage amounts from the mobile computing device; an infusion detection mechanism adapted to detect events related to insulin infusions; a processor that determines the percentage of insulin that remains active for each insulin infusion; and a display adapted to display the amount of active insulin remaining in the user as a percentage of the last injection of insulin.

[0278] Embodiment 19: A system as described in embodiment 18, wherein the reusable accessory detects or identifies the dose of insulin for each event associated with insulin infusion, and the display displays the amount of active insulin remaining in the user as units of insulin, and optionally can include multiple insulin doses at different times.

[0279] Embodiment 20: A system described in any one of embodiments 1 to 19, wherein the reusable accessory does not detect or identify the insulin dose for each event related to insulin injection.

[0280] Embodiment 21: A method for managing diabetes therapy, the method comprising: detecting an event related to the injection of a medication from a medication injection pen in response to the attachment or detachment of a reusable accessory to the medication injection pen; and determining a percentage of the medication that remains active for the medication injection based on a current time and a time of the injection-related event, wherein the event is related to the attachment or detachment of the reusable accessory to the medication injection pen.

[0281] Embodiment 22: A smart electronics module that can be integrated with an injection pen, wherein a reusable accessory is adapted to be reversibly attached to the medication injection pen, and the reusable accessory is configured to detect an event related to the injection of a medication from the medication injection pen and identify a percentage of the medication that remains active for the injection of the medication based on a current time and the time of the event related to the injection.

[0282] Embodiment 23: A system, method, or device described in any one of embodiments 1 to 22, wherein the blood glucose data and / or glucose data is or is based on interstitial fluid glucose concentration.

[0283] Embodiment 24: A system, method, or device described in any one of embodiments 1 to 23, wherein the blood glucose data and / or glucose data is a blood glucose level correlated to interstitial fluid glucose concentration.

[0284] Embodiment 25: A system, method, or device described in any one of embodiments 1 to 24, wherein the blood glucose data and / or glucose data is a blood glucose level.

[0285] Additional non-limiting embodiments of the present disclosure relate generally to insulin infusion assistance systems, methods, and devices.

[0286] and a computing device remote from the first reusable insulin dose detector; wherein the mobile application, while executing on the computing device, is configured to: receive insulin therapy settings including the first insulin type settings; identify first timing data corresponding to one or more first insulin delivery event times for one or more of the first insulin delivery events; analyze the glucose data in combination with the first timing data; and determine an adjustment recommendation or an automatic change of the insulin therapy settings in response to the analysis.

[0287] Embodiment 2: The system of embodiment 1, further comprising a remote server adapted to receive the glucose data and the first timing data via an internet connection between the mobile computing device and the remote server.

[0288] Embodiment 3: A system described in any one of embodiments 1 to 2, wherein the remote server is configured to analyze the first timing data and glucose data and determine an adjustment recommendation or an automatic change in insulin therapy settings in response to the analysis.

[0289] Embodiment 4: The system of any one of embodiments 1 to 3, wherein the mobile application is configured to analyze the first timing data and glucose data and determine an adjustment recommendation or an automatic change in insulin therapy settings in response to the analysis.

[0290] Embodiment 5: A system described in any one of embodiments 1 to 4, wherein the first reusable insulin dose detector is a first reusable accessory, the first disposable component is a first insulin injection pen or a first insulin inhaler, the first insulin delivery event is associated with an insulin injection or insulin inhalation, and the first reusable accessory is adapted to reversibly connect to the first insulin injection pen or the first insulin inhaler.

[0291] Embodiment 6: A system described in any one of embodiments 1 to 5, wherein the first reusable accessory is a first replacement cap adapted to be placed over the needle of a first insulin injection pen or adapted to be placed over the inhalation pathway of a first insulin inhaler, and the first replacement cap is configured to detect a cap attachment event and / or a cap removal event.

[0292] Embodiment 7: A system described in any one of embodiments 1 to 6, wherein the first reusable accessory is configured to detect a first insulin delivery event in response to one or more cap-on and / or cap-off events.

[0293] Embodiment 8: A system described in any one of embodiments 1 to 7, wherein the first reusable insulin dose detector is a first reusable smart pen or a first smart inhaler, the first disposable component comprises a first insulin cartridge, and the first reusable smart pen or first smart inhaler is configured to receive a first insulin injection cartridge and is configured to be activated by a user to deliver a first insulin type from the first insulin cartridge.

[0294] Embodiment 9: The system of any one of embodiments 1 to 8, further comprising at least a second reusable insulin dose detector reversibly connectable to a second disposable component comprising a chamber for a second insulin type and adapted to form at least a part of a second insulin manual delivery assembly, wherein the second reusable accessory comprises a second wireless communication interface configured to wirelessly receive a second insulin type setting of the insulin delivery settings from the mobile application, wherein the second reusable insulin dose detector is configured to detect second insulin delivery events associated with the second insulin manual delivery assembly, and wherein the recommendation system is configured to identify second timing data corresponding to one or more second insulin delivery event times of the one or more second insulin delivery events, analyze the glucose data in combination with the first timing data and the second timing data, and determine an adjustment recommendation or an automatic change to the insulin delivery settings in response to the analysis.

[0295] Embodiment 10: A system described in any one of embodiments 1 to 9, wherein the second reusable insulin dosage detector is configured to wirelessly receive glucose data from the first glucose sensor system.

[0296] Embodiment 11: A system described in any one of embodiments 1 to 10, wherein while the first glucose sensor system is in wireless communication with the second reusable insulin dose detector, the system disables wireless communication of glucose data from the first glucose sensor system to the first reusable insulin dose detector.

[0297] Embodiment 12: The system of any one of embodiments 1 to 11, wherein the second reusable insulin dose detector is selected from the group consisting of a second smart pen configured to receive a second disposable pen cartridge containing a second insulin type, a second smart inhaler configured to receive a second disposable inhalable insulin cartridge containing a second insulin type, and a second replacement pen cap adapted to be secured over the needle of the second disposable insulin injection pen containing the second insulin type, or a second replacement inhaler cap adapted to be secured over the inhalation pathway of the second insulin inhaler.

[0298] Embodiment 13: A system described in any one of embodiments 1 to 12, wherein the first insulin type is selected from the group consisting of long-acting insulin, rapid-acting insulin, and a combination of long-acting insulin and rapid-acting insulin.

[0299] Embodiment 14: A system described in any one of embodiments 1 to 13, wherein the first glucose sensor system is a blood glucose meter adapted to analyze blood in vitro.

[0300] Embodiment 15: A system described in any one of embodiments 1 to 14, wherein the recommendation system is adapted to analyze timing data and glucose data of one or more insulin delivery events to recommend adding a second glucose sensor system selected from the group consisting of a continuous glucose monitor and a flash glucose monitor.

[0301] Embodiment 16: The system of any one of embodiments 1 to 15, wherein the first glucose sensor system is a flash glucose monitor.

[0302] Embodiment 17: A system described in any one of embodiments 1 to 16, wherein the first glucose sensor system is configured to communicate a limited glucose data set to a mobile application via a first communication technology having a first communication range and to communicate a reliable glucose data set to the first or second reusable insulin dosage detector via a second communication technology having a second communication range, the first communication range being greater than the second communication range.

[0303] Embodiment 18: A system described in any one of embodiments 1 to 17, wherein the mobile application is capable of receiving glucose data directly from the first glucose sensor system via the first communication technology and the second communication technology.

[0304] Embodiment 19: A system described in any one of embodiments 1 to 18, wherein the first reusable insulin dose detector comprises a display, and the display is configured to provide a recommended first insulin dose of the first insulin type based on the first insulin setting.

[0305] Embodiment 20: A system described in any one of embodiments 1 to 19, wherein the first reusable insulin dosage detector or mobile application is configured to issue an alert if the detected dosage of the first insulin type does not comply with the first insulin setting.

[0306] Embodiment 21: A system described in any one of embodiments 1 to 20, wherein the system is adapted to identify one or more insulin doses of a first insulin type associated with each detected first insulin delivery event.

[0307] Embodiment 22: A method of assisted manual administration of insulin, comprising: receiving a first insulin delivery event associated with a first insulin manual delivery assembly, the first insulin manual delivery assembly comprising a first reusable insulin dose detector reversibly connected to a first disposable component and adapted to detect the first insulin delivery event; identifying first timing data corresponding to one or more first insulin delivery event times for one or more of the first insulin delivery events; analyzing glucose data in combination with the first timing data; and determining an adjustment recommendation or an automatic change in insulin therapy settings in response to the analysis.

[0308] Embodiment 23: The method of embodiment 22, further comprising receiving a first insulin delivery event at a communication interface configured to wirelessly communicate with the first reusable insulin dose detector.

[0309] Embodiment 24: The method of any one of embodiments 1 to 23, further comprising receiving a second insulin delivery event associated with a second insulin manual delivery assembly, the second insulin manual delivery assembly comprising a second reusable insulin dose detector reversibly connected to the second disposable component and adapted to detect the second insulin delivery event, and determining a second adjustment recommendation or an automatic change in the second insulin therapy setting in response to the second insulin delivery event.

[0310] Embodiment 25: The method of any one of embodiments 1 to 24, further comprising receiving glucose data from the first reusable dosage detector.

[0311] Embodiment 26: The system of any one of embodiments 1 to 25, further comprising receiving glucose data from the first glucose sensor system.

[0312] Embodiment 27: A system for remotely specifying a manual dose of insulin, the system comprising: receiving a first insulin delivery event associated with a first insulin manual delivery assembly, the insulin delivery event being received at a communication interface configured to communicate with a reusable insulin dose detector; identifying first timing data corresponding to one or more first insulin delivery event times of the one or more first insulin delivery events; analyzing glucose data in combination with the first timing data; determining an adjustment recommendation or an automatic change in insulin therapy settings in response to the analysis; and providing the adjustment recommendation or the automatic change in insulin therapy settings to the communication interface for transmission to the reusable insulin dose detector.

[0313] Embodiment 28: A system for assisting with manual insulin administration, the system comprising: a recommendation system comprising a mobile application executing on a computing device, the mobile application configured to determine insulin delivery adjustment recommendations and changes to insulin treatment settings in response to glucose data associated with one or more insulin delivery events, the recommendation system further configured to detect a first reusable insulin dosage detector and, in response to the detection, create an insulin manual delivery assembly profile associated with an insulin manual delivery assembly of the first reusable insulin dosage detector and assign one or more insulin treatment settings to the insulin manual delivery assembly profile.

[0314] Embodiment 29: The system described in embodiment 28, wherein the recommendation system is configured to load one or more insulin treatment settings from memory or create one or more insulin treatment settings in response to one or more physiological parameters associated with a user of the recommendation system.

[0315] Embodiment 30: A system described in any one of embodiments 1 to 29, wherein the recommendation system is configured to provide a user prompt on a display of the computing device, the user prompt including one approval for pairing with the first reusable insulin dosage detector.

[0316] Embodiment 31: A system described in any one of embodiments 1 to 30, wherein the recommendation system is configured to send one or more of insulin delivery adjustment recommendations and changes to insulin therapy settings to the reusable insulin dosage detector.

[0317] Embodiment 32: A system described in any one of embodiments 1 to 31, wherein the recommendation system is further configured to receive an unpairing command with the second insulin dosage detector and, in response to the unpairing command, delete or disable a second insulin manual delivery assembly profile associated with the second insulin dosage detector.

[0318] Embodiment 33: A system described in any one of embodiments 1 to 32, wherein the recommendation system is further configured to detect a second reusable insulin dose detector and, in response to the detection, create a second insulin manual delivery assembly profile associated with the second insulin manual delivery assembly of the second reusable insulin dose detector and specify one or more second insulin therapy settings in the second insulin manual delivery assembly profile.

[0319] Embodiment 34: A system described in any one of embodiments 1 to 33, wherein the recommendation system is configured to send insulin delivery adjustment recommendations and changes to insulin therapy settings to the first and second reusable insulin dosage detectors.

[0320] Embodiment 35: A system described in any one of embodiments 1 to 34, wherein the recommendation system is configured to receive glucose data associated with one or more insulin delivery events of the first and second reusable insulin dosage detectors.

[0321] Embodiment 36: A system described in any one of embodiments 1 to 35, wherein the first reusable insulin dose detector and the second reusable insulin dose detector are each a different one of a reusable accessory, a smart insulin pen, and a smart insulin.

[0322] Embodiment 37: A system for assisting in manual administration of insulin, the system comprising: at least a first glucose sensor system adapted to wirelessly transmit glucose data; smart electronics coupled with one or more portions of a first insulin manual delivery assembly, the smart electronics operably connected to at least a first disposable component comprising a chamber for a first insulin type to form at least a part of the first insulin manual delivery assembly; at least a first reusable insulin dose detector configured to detect a first insulin delivery event associated with the first insulin manual delivery assembly; a recommendation system comprising: a mobile application; and a computing device remote from the first reusable insulin dose detector, wherein the mobile application, while executing on the computing device, is configured to receive insulin therapy settings including the first insulin type settings, identify first timing data of the one or more first insulin delivery events corresponding to the one or more first insulin delivery event times, analyze the glucose data in combination with the first timing data, and determine an adjustment recommendation or an automatic change of the insulin therapy settings in response to the analysis.

[0323] Embodiment 38: A system, method, or device described in any one of embodiments 1 to 37, wherein the glucose data is an interstitial fluid glucose concentration or is based on an interstitial fluid glucose concentration.

[0324] Embodiment 39: A system, method, or device described in any one of embodiments 1 to 38, wherein the glucose data is a blood glucose level correlated to interstitial fluid glucose concentration.

[0325] Embodiment 40: A system, method, or device described in any one of embodiments 1 to 39, wherein the glucose data is a blood glucose level.

[0326] A further non-limiting embodiment of the present disclosure generally relates to a pen cap for a medication injection pen having a temperature sensor.

[0327] Embodiment 1: A replacement pen cap for a medication injection pen comprising at least one temperature sensor configured to monitor a temperature of a medication within the medication injection pen while the replacement pen cap is associated with the medication injection pen cap, the replacement pen cap adapted to detect potential administration events, the replacement pen cap adapted to receive analyte measurement data from an analyte sensor system, and the replacement pen cap adapted to determine whether the medication within the medication injection pen has denatured based on a combination of data from the at least one temperature sensor and the analyte measurement data received following each detected potential administration event.

[0328] Embodiment 2: A replacement pen cap according to embodiment 1, wherein the at least one temperature sensor is configured to monitor a temperature range when the pen cap is associated with an insulin pen.

[0329] Embodiment 3: A replacement pen cap described in any one of embodiments 1 to 2, wherein the pen cap is configured to provide at least one of a warning or an alert to the user when a selected threshold temperature value is detected, the alert being presented as a visual indication when the threshold is exceeded and an audible warning being triggered when the threshold is exceeded and the pen cap receives a glucose value indicating that one or more previous insulin doses were ineffective.

[0330] Embodiment 4: A pen cap according to any one of embodiments 1 to 3, wherein the pen cap is configured to provide a user with data relating to the temperature exposure of insulin.

[0331] Embodiment 5: A smart electronics module that can be integrated with a medication injection pen comprising at least one temperature sensor, the at least one temperature sensor configured to monitor a temperature of a medication within the medication injection pen while the smart electronics module is enabled, the smart electronics module configured to detect potential administration events, the smart electronics module configured to receive analyte measurement data from an analyte sensor system, and the smart electronics module configured to determine whether the medication within the medication injection pen has denatured based on a combination of data from the at least one temperature sensor and the analyte measurement data received following each detected potential administration event.

[0332] Embodiment 6: A system, method, or device according to any one of embodiments 1 to 5, wherein the glucose data is an interstitial fluid glucose concentration or is based on an interstitial fluid glucose concentration.

[0333] Embodiment 7: A system, method, or device described in any one of embodiments 1 to 6, wherein the glucose data is blood glucose levels correlated to interstitial fluid glucose concentrations.

[0334] Embodiment 8: A system, method, or device described in any one of embodiments 1 to 7, wherein the glucose data is a blood glucose level.

[0335] Further non-limiting embodiments of the present disclosure relate generally to user interfaces for diabetes management systems and devices.

[0336] Embodiment 1: A diabetes management system comprising: a computing device including a memory and a processor configured to receive at least one data point related to a subject's prior insulin use and calculate a sliding-scale glucose correction data set based at least in part on the at least one data point related to the subject's prior insulin use.

[0337] Embodiment 2: The system of embodiment 1, further comprising an insulin pen assembly, wherein the computing device is configured to provide at least some data from slide scale glucose correction data set in the insulin pen assembly, and the insulin pen assembly is configured to display at least some of the data as a recommended correction insulin dose.

[0338] Embodiment 3: A system described in any one of embodiments 1-2, wherein the insulin pen assembly comprises an insulin pen and a reusable accessory for a disposable insulin pen.

[0339] Embodiment 4: A system described in any one of embodiments 1 to 3, wherein the reusable accessory is a replacement pen cap for a disposable insulin pen.

[0340] Embodiment 5: A system described in any one of embodiments 1 to 4, wherein the insulin pen assembly is a reusable insulin injection pen adapted to receive a prefilled insulin cartridge for administering insulin.

[0341] Embodiment 6: A system described in any one of embodiments 1 to 5, wherein the insulin pen assembly is adapted to receive blood glucose data from the glucose sensor system, and the recommended correction insulin dose is based on the received blood glucose data and the sliding scale glucose correction data set.

[0342] Embodiment 7: A system described in any one of embodiments 1 to 6, wherein the sliding scale glucose-corrected data set is a linear scale based on at least one data point that includes an insulin sensitivity factor.

[0343] Embodiment 8: A system described in any one of embodiments 1 to 7, wherein the sliding scale glucose correction data set is a non-linear scale based on at least one data point comprising a plurality of data points input into a computing device.

[0344] Embodiment 9: A system described in any one of embodiments 1 to 8, wherein the plurality of data points each include a range of glucose values ​​and an associated correction dose.

[0345] Embodiment 10: A system described in any one of embodiments 1 to 9, wherein the range of glucose values ​​and associated correction doses are based on the subject's insulin use history.

[0346] Embodiment 11: A diabetes management system comprising: a computing device including a memory and a processor configured to display a plurality of photographs of meals categorized into a plurality of categories each having a similar glycemic impact, and to receive user input for each of the plurality of categories of a number of units of insulin that the user would normally administer for the meals included in that category; and an insulin pen assembly having a pen display, wherein the computing device is configured to provide the user input for each category to the insulin pen, and the pen display provides at least one recommended insulin dosage based at least in part on the user input received for each category.

[0347] Embodiment 12: The system of embodiment 11, wherein the insulin pen assembly displays recommended insulin doses for multiple categories.

[0348] Embodiment 13: A system described in any one of embodiments 1 to 12, wherein the computing device receives user input defining a correction factor based on blood glucose levels, the insulin pen assembly is adapted to receive blood glucose data from the glucose sensor system, the insulin pen assembly receives the correction factor from the computing device, and each recommended insulin dose is based on the correction factor and the blood glucose data.

[0349] Embodiment 14: A system described in any one of embodiments 1 to 13, wherein the correction factor is a sliding scale glucose correction data set.

[0350] Embodiment 15: A system described in any one of embodiments 1 to 14, wherein the insulin pen assembly comprises an insulin pen and a reusable accessory for a disposable insulin pen.

[0351] Embodiment 16: A system described in any one of embodiments 1 to 15, wherein the reusable accessory is a replacement pen cap for a disposable insulin pen.

[0352] Embodiment 17: A system, method, or device described in any one of embodiments 1 to 16, wherein the glucose data is an interstitial fluid glucose concentration or is based on an interstitial fluid glucose concentration.

[0353] Embodiment 18: A system, method, or device described in any one of embodiments 1 to 17, wherein the glucose data is a blood glucose level correlated to interstitial fluid glucose concentration.

[0354] Embodiment 19: A system, method, or device described in any one of embodiments 1 to 18, wherein the glucose data is a blood glucose level.

[0355] Additional non-limiting embodiments of the present disclosure relate generally to warnings and alerts in diabetes management systems.

[0356] and a mobile application on a remote computing device adapted to automatically receive glucose data via the second wireless communication method, wherein the mobile application issues an alert in the one or more signal outputs in response to the received glucose data.

[0357] Embodiment 2: The diabetes management system of embodiment 1, further comprising an insulin type detector configured to detect the type of insulin in the chamber of the insulin manual delivery device, wherein the first reusable accessory is configured to issue an alert in one or more signal outputs in response to the detector, the alert indicating an incorrect insulin type.

[0358] Embodiment 3: A diabetes management system as described in any one of embodiments 1-2, further comprising an insulin type detector configured to detect the type of insulin in the chamber of the insulin manual delivery device, and wherein the mobile application is configured to issue an alert in one or more signal outputs in response to the detector, the alert indicating an incorrect insulin type.

[0359] Embodiment 4: A diabetes management system described in any one of embodiments 1 to 3, wherein the mobile application is configured to compare the detected insulin type with the predicted insulin type and output an error signal in response to the comparison.

[0360] Embodiment 5: A diabetes management system according to any one of embodiments 1 to 4, wherein the mobile application is configured to determine a predicted insulin type in response to an administration action or based on user-provided parameters.

[0361] Embodiment 6: A diabetes management system described in any one of embodiments 1 to 5, further comprising a user verification system configured to present prompts to the user in response to administration operations and one or more diabetes management system modes.

[0362] Embodiment 7: A diabetes management system described in any one of embodiments 1 to 6, wherein the user verification system is configured to present a physiological parameter prompt in response to a hyper system monitoring mode and a high correction dose associated with a recent administration operation.

[0363] Embodiment 8: A diabetes management system according to any one of embodiments 1 to 7, further comprising a user verification system configured to present a glucose measurement prompt in response to a current time or time period.

[0364] Embodiment 9: A diabetes management system described in any one of embodiments 1 to 8, wherein the first reusable accessory does not receive glucose data from the first glucose sensor system via the first wireless communication method.

[0365] Embodiment 10: A diabetes management system described in any one of embodiments 1 to 9, wherein the first reusable accessory is adapted to receive glucose data from the mobile application via a second wireless communication method.

[0366] Embodiment 11: The diabetes management system according to any one of embodiments 1 to 10, wherein the first communication method is short-range wireless communication and the second communication method is Bluetooth Low Energy.

[0367] Embodiment 12: A diabetes management system according to any one of embodiments 1 to 11, wherein the alert is based on a received glucose value below a threshold.

[0368] Embodiment 13: A diabetes management system according to any one of embodiments 1 to 12, wherein the alert is based on a predicted future glucose value below a threshold.

[0369] Embodiment 14: A diabetes management system described in any one of embodiments 1 to 13, wherein the first accessory is adapted to detect insulin administration from the first insulin injection pen and communicate administration data to the mobile application via a second wireless communication method.

[0370] Embodiment 15: A diabetes management system according to any one of embodiments 1 to 14, wherein the alert is based at least in part on administration data.

[0371] Embodiment 16: The diabetes management system of any one of embodiments 1 to 15, wherein the first insulin injection pen is a long-acting insulin injection pen and the alert is a missed dose alert.

[0372] Embodiment 17: A diabetes management system according to any one of embodiments 1 to 16, wherein the alert is in response to a high correction dose, a detected administration event, and a timeout.

[0373] Embodiment 18: A diabetes management system according to any one of embodiments 1 to 17, wherein the alerts are in response to missed administration events, high correction doses, and timeouts.

[0374] Embodiment 19: A diabetes management system comprising: one or more signal outputs configured to present one or more of a warning, an alert, and a notification discernible by a user; at least a first glucose sensor system adapted to wirelessly transmit glucose data via a first wireless communication method having a first communication range and a second wireless communication method having a second communication range, wherein the first wireless communication method requires user action and the second wireless communication method is automatic, and the second communication range is greater than the first communication range; at least a first smart electronics module configured to be integrated with a first insulin injection pen, the first smart electronics module configured to wirelessly receive glucose data from the first glucose sensor system via the first wireless communication method upon movement within the first communication range; and a mobile application on a remote computing device adapted to automatically receive glucose data via the second wireless communication method, the mobile application issuing a warning in the one or more signal outputs at least in part in response to the received glucose data.

[0375] Embodiment 20: A system, method, or device described in any one of embodiments 1 to 19, wherein the glucose data is an interstitial fluid glucose concentration or is based on an interstitial fluid glucose concentration.

[0376] Embodiment 21: A system, method, or device described in any one of embodiments 1 to 20, wherein the glucose data is blood glucose levels correlated to interstitial fluid glucose concentrations.

[0377] Embodiment 22: A system, method, or device described in any one of embodiments 1 to 21, wherein the glucose data is a blood glucose level.

[0378] Additional non-limiting embodiments of the present disclosure relate generally to monitoring devices for diabetes management systems.

[0379] Embodiment 1: A diabetes management system comprising an insulin delivery device and a monitoring device for detecting at least one characteristic related to the insulin delivery device.

[0380] Embodiment 2: The system of embodiment 1, wherein the insulin delivery device comprises an insulin pen and the monitoring device comprises a pen cap.

[0381] Embodiment 3: The system described in embodiment 2, wherein the pen cap is configured to detect at least one of a cap-on event in which the pen cap is secured onto the therapy delivery portion of the insulin pen, or a cap-off event in which the pen cap is at least partially removed from the therapy delivery portion of the insulin pen.

[0382] Embodiment 4: A system described in any one of embodiments 1 to 3, wherein the monitoring device is configured to provide the user with at least one alert or warning regarding previous and / or future use of the insulin delivery device.

[0383] Embodiment 5: A system described in any one of embodiments 1 to 4, wherein the monitoring device is configured to provide the user with at least one alert or warning regarding previous or future use of the insulin delivery device.

[0384] Embodiment 6: A system described in any one of embodiments 1 to 5, wherein the monitoring device is configured to display data regarding previous or future use of the insulin delivery device.

[0385] Embodiment 7: A system according to any one of embodiments 1 to 6, wherein the monitoring device is configured to display data relating to the user's blood glucose level.

[0386] Embodiment 8: A system described in any one of embodiments 1 to 7, wherein the monitoring device is configured to display data regarding the dosage.

[0387] Embodiment 9: A system described in any one of embodiments 1 to 8, wherein the monitoring device is configured to allow a user to select the dosage.

[0388] Embodiment 10: A system described in any one of embodiments 1 to 9, wherein the monitoring device is configured to allow a user to select one of a number of predetermined dosages.

[0389] Embodiment 11: The system of embodiment 10, wherein the monitoring device is configured to display the number of predetermined doses based on each dosage suggestion for the selected meal size.

[0390] Embodiment 12: A system described in any one of embodiments 1 to 11, wherein the monitoring device is configured to display data regarding the time since the previous administration was administered.

[0391] Embodiment 13: A system described in any one of embodiments 1 to 12, wherein the time related to the previous administration is assumed based on a previous event detected by the monitoring device.

[0392] Embodiment 14: The system of embodiment 13, wherein the time associated with the previous administration is based on a cap removal event detected by a monitoring device comprising the pen cap.

[0393] Embodiment 15: A diabetes management system comprising a device including a processor, the device configured to detect an image of an insulin delivery device and identify a remaining amount of insulin contained in the insulin delivery device.

[0394] Embodiment 16: A method of managing drug therapy, comprising: removing a monitoring device from an insulin delivery device; replacing the monitoring device on the insulin delivery device; and identifying at least one characteristic related to the insulin delivery device in response to at least one of removing the monitoring device from the insulin delivery device or replacing the monitoring device on the insulin delivery device.

[0395] Embodiment 17: The method of embodiment 16, further comprising providing at least one therapeutic suggestion for the insulin delivery device to the user using the monitoring device based on the at least one characteristic.

[0396] Embodiment 18: The method of embodiment 16 or 17, further comprising providing at least one alert or warning to the user using a monitoring device regarding previous or future use of the insulin delivery device based on at least one characteristic.

[0397] Embodiment 19: The method of any one of embodiments 1 to 18, further comprising displaying, using a monitoring device, data regarding previous or future use of the insulin delivery device based on the at least one characteristic.

[0398] Embodiment 20: The method of any one of embodiments 1 to 19, further comprising using a monitoring device to provide a number of predetermined dosages for user selection. [Explanation of symbols]

[0399] 10,12 Insulin Therapy Management System 20 People with diabetes (PWD) 101 Glucose Sensor System 102 First Accessory 103 Second Accessory 104 Mobile Applications 105 Web Services 106,107 Manual delivery device 108 Network 110 Long-acting insulin injection pen 112 Long-acting Pen Cap 113 Button 114 Display 116 icons 117 Long-acting insulin 120 Rapid-Acting Insulin Injection Pen 122 Instant-acting pen cap 123 Button 124 display 125 Time 126a, 126b, 126c Meal Icons 126d Correction Dose Icon 127a, 127b, 127c Food-Related Dosage Recommendations (Dietary Recommendations) 127d Recommended Correction Dose 128 notification icons 129 Blood Glucose Data 130 Glucose Monitor (GCM) 140 Mobile Devices or Mobile Applications 150 Blood sugar meter (BGM) 211,221 Bluetooth Low Energy (BLE) communication link 231 Near Field Communication (NFC) Link 232 NFC and BLE communication links 241 WiFi or cellular connection 250 Web Services

Claims

1. 1. A pen cap for an insulin pen, comprising: at least one input device configured to receive glucose data of the user; At least one circuit configured to detect an insulin pen dosing operation event, wherein the dosing operation event is inferred based on an uncap event of the pen cap from the insulin pen and a cap event of the pen cap to the insulin pen; at least one user interface configured to display a current glucose level or glucose trend data based on the glucose data and configured to display a treatment recommendation, the treatment recommendation including a recommended correction dose of insulin; and a memory configured to store user-specific dosage parameters for providing the treatment recommendation, the user-specific dosage parameters including an insulin sensitivity factor and a target glucose value of the user; at least one processor configured to identify content to be presented by the at least one user interface, the at least one processor configured to use information related to the dispensing operation event; Equipped with When the at least one user interface is configured to display the treatment recommendation, the pen cap is configured to prevent displaying the recommended correction dose of insulin for a period of time after the administration operation event, the recommended correction dose being based at least in part on the insulin sensitivity factor and the target glucose value stored in the memory.

2. The pen cap of claim 1 , wherein the recommended correction dose comprises a dose of rapid-acting insulin.

3. 3. A pen cap according to claim 1 or 2, wherein said period is at least 3 hours.

4. 4. The pen cap of claim 1, wherein the at least one circuit comprises a sensor configured to detect when the pen cap is applied to or removed from the insulin pen.

5. The pen cap of claim 4 , wherein the sensor comprises a leaf spring, an optical sensor, a mechanical sensor, an electronic sensor, a magnetic sensor, or a combination thereof.

6. A pen cap as described in any one of claims 1 to 5, wherein the at least one user interface is further configured to display treatment-related information, the treatment-related information including a current estimated glucose value, a current glucose trend, a glucose change rate, or a combination thereof.

7. The pen cap of claim 1 , wherein the treatment recommendation further comprises a recommended dietary dosage.

8. 8. The pen cap of claim 1, wherein the user-specific dosage parameters further include a total daily basal dose, a carbohydrate-to-insulin ratio, a correction dose based on a range of glucose values, a total daily insulin dose, a recommended meal dose, or a combination thereof.

9. The pen cap of claim 1 , wherein the recommended correction dose is based at least in part on a current glucose value.

10. The pen cap of claim 1 , wherein the pen cap is configured to display the time elapsed since the dispensing event.

11. 11. The pen cap of claim 1, wherein the pen cap is configured to communicate with a glucose sensor system, the glucose sensor system comprising a glucose sensor configured to contact a bodily fluid of a user.

12. The pen cap of claim 1 , wherein the content includes an indication of the active insulin remaining in the user based on the time of the dispensing action event and the current time.

13. The pen cap of claim 1 , wherein the content includes a notification indicating that a user recently administered insulin using the insulin pen based on the time of the administration operation event and the current time.

14. A pen cap according to any one of claims 1 to 13, wherein the pen cap is configured to display the recommended correction dose after the period of time.

15. 15. The pen cap of claim 14, wherein the pen cap is configured to continue to display the recommended correction dose for a second period of time.

16. A pen cap according to any preceding claim, wherein the period is based on the detection of a subsequent dispense event.

17. 1. A method of administering medication therapy with a manual medication delivery device, comprising: receiving glucose data of the user from a glucose sensor; detecting a dose actuation event in a pen cap removably attached to the manual medication delivery device; storing a record of the dispensing operation event; providing one or more medication dosage recommendations in response to the glucose data; The method, wherein the pen cap is configured to prevent displaying a medication dosage recommendation for a period of time after the dispense operation event.

18. 18. The method of claim 17, wherein the medication dosage recommendation comprises a recommendation for a dosage of fast-acting insulin.

19. 19. The method of claim 17 or 18, wherein the period is at least 3 hours.

20. 20. The method of any one of claims 17 to 19, further comprising displaying a recommended correction dose on the pen cap after said period of time.

21. the manual medication delivery device includes a medication injection pen; 21. The method of claim 17, wherein the dispensing operation events include an uncapping event of the pen cap from the medication injection pen and an uncapping event of the pen cap to the medication injection pen.

22. 22. The method of any one of claims 17 to 21, wherein the period is based on the detection of a subsequent dispensing operation event.

Images